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5-HT     5-Hydroxytryptamine, serotonin 
ACC     Anterior cingulate cortex 
AI     Asymmetry index 
BI     Binding index 
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A. Introduction 
Providing adequate pain relief (both in humans and animals) remains a challenge even 
after decades of research and continuous evolutions in pain medication. Major reasons for 
this are the existing lack in profound understanding of the exact site of action of pain 
medication in combination with the impaired access to controlled substances, in the case of 
opioids. The cause for this impaired access to opioids has been studied by the World Health 
Organization (WHO), which found that there was an imbalance between the prevention of 
abuse of controlled substances and their use for legitimate medical purposes (WHO, 2011).  
According to the WHO, the number of people suffering from inadequately treated or 
untreated pain is far beyond several millions. These include cancer patients, but also other 
chronic pain patients and people with severe acute pain (WHO, 2012a and 2012b). In 
veterinary medicine, chronic pain is also an important issue in cases of cancer and chronic 
inflammatory processes (Robertson, 2005; Rusbridge and Jeffery, 2008; Fox, 2010; Grubb, 
2010a and 2010b).  
Better understanding how opioids work and how they interact with the central nervous 
system can contribute to the expanding research on (equivalent or better) alternative drugs for 
pain management. Accordingly, in the field of opioids, myriad studies have been conducted 
(either in human subjects or in animal models) on the topic of problems associated with long-
term (ab)use of opioids. As mentioned, animals (rodents mainly, but also higher species) 
have been used for decades as study models for humans. Additionally, from a veterinary 
medicine point-of-view, research on pain management in animals as such, has gained interest 
only in the last decade, leading to a booming research field. Caring for our animals and 
giving them a good quality of life is becoming more and more important. One of the basic 
ideas that comes with that is the need to provide efficient pain relief to our animals. This has 
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been achieved in the past by using drugs that were designed for human use. However, the 
differences between man and animal and between different animals as well, have given the 
opportunity to investigate these drugs and their use in animals. Causes for variations in drug 
action are for instance differences in drug uptake, metabolization, excretion, penetration of 
natural barriers (e.g. blood brain barrier), etc. Next to pharmacokinetic and –dynamic studies, 
functional imaging can provide information on specific interactions of drugs with the target 
organs in vivo and in a non-invasive manner. Single photon emission computed tomography 
(SPECT) of the brain is one of these functional imaging modalities that is frequently used in 
drug research.  
Over the years, our research group has successfully invested great effort in developing the 
SPECT technique for its use in small animals and in evaluating several radioligands for brain 
imaging in dogs. To this day, visualizing the signaling components of the serotonergic (5-
HT) and the dopaminergic (DA) system, as well as cerebral blood flow in dogs has led to a 
rather unique approach to SPECT. On the one hand, progress was made with regards to 
canine brain pathology, such as behavioral disorders and epilepsy (Peremans et al., 2003b; 
Martlé et al., 2009). On the other hand, data from these studies have also provided 
information of great value for human medicine, for example the work done on the serotonin-
2A receptors (5-HT2A) (Vermeire et al., 2009).  
In addition to the use of SPECT in a neutral, at rest, basal brain state, it is interesting to 
combine this imaging technique with certain drugs in order to gain insights on how they 
influence the brain and thus, to better understand how they work. As mentioned previously, 
next to the evaluation of neurotransmitter systems, regional cerebral blood flow can be 
estimated. These regional differences in cerebral blood flow are known to be a measure for 
brain activity (Sokoloff et al., 1977; Gerrits et al., 1998). Therefore, SPECT is a very useful 
tool to assess the action of different drugs on the brain. In that perspective, this imaging 
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technique may provide further information on the mode of action of opioids. In this study the 
effect of morphine on the 5-HT2A receptor and on brain regional perfusion was investigated. 
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B. Pain modulation and the opioid system 
1. Mu opioid receptor agonists: mode of action 
Morphine is a potent analgesic derived from the opium poppy, Papaver somniferum 
(Figure 1). It is only after being used (and misused) for a long time that researchers finally 
unraveled the underlying mode of action of opioids in the 1970s by discovering the opioid 
receptors. There are three known opioid receptors in man and animal: mu, delta and kappa 
opioid receptors, i.e. MOR, DOR and KOR respectively (Mansour et al., 1995a; Peckys and 
Landwehrmeyer, 1998). Based on the type of interaction of the opioid with one or another 
opioid receptor, opioids can be divided in different groups with different properties: full 
agonists, partial agonists, agonist/antagonists and full antagonists (Lamont and Matthews, 
2007). Morphine belongs to the full MOR agonist group, next to methadone and fentanyl.  
Figure 1. The opium 
poppy Papaver 
somniferum (A) from 
which the latex is 
harvested by making 
incisions in the seed 
pod (B) and opiate 
alkaloids like morphine 
(C) can be extracted.   
 
Opioid receptors are G-protein coupled receptors (GPCRs) that produce inhibitory effects 
in neurons (review: Connor and Christie, 1999). Receptor activation results in inhibition of 
adenylyl cyclase causing a decrease in cyclic adenosine monophosphate (cAMP), neuronal 
hyperpolarization via activation of K+ channels, and inhibition of neurotransmitter release via 
inhibition of Ca++ channels (review: Reisine, 1995; Standifer and Pasternak, 1997). The 
receptors consist of an extracellular ligand-binding part (N-terminus), a transmembranar part 
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and an intracellular part that interacts with a heterotrimeric G-protein that consists of three 












Figure 2. Schematic representation of a G-protein coupled 
receptor, in this case a mu opioid receptor (MOR).  
Opioid receptors are located both on pre- and postsynaptic neuronal membranes as shown 
by neuronal targeting (Arvidsson et al., 1995; Abbadie et al., 2002). Presynaptically, opioids 
inhibit the release of neurotransmitters, such as glutamate, gamma-aminobutyric acid 
(GABA) and substance P, through inhibition of Ca++ channels (Bradford et al, 1986; Tanaka 
and North, 1994; Aicher et al., 2000a and 2000b). Postsynaptically, receptor activation causes 
opening of G-coupled inwardly rectifying K+ channels and thus induces hyperpolarization of 
the cell, preventing excitation and reducing the conductance of action potentials (Grudt and 
Williams, 1993; Tanaka and North, 1994). 
Based on the localization of the ORs, it is clear that opioids have an important role in the 
transmission, modulation and perception of pain. Opioid receptors can be found in all key 
sites for nociception, i.e. supraspinally, spinally and in the peripheral nervous system.  
The first level at which opioids can modulate nociception, is at the periphery where ORs 
can be found in the primary afferents and the dorsal root ganglia (DRG) (Atweh and Kuhar, 
1977; Arvidsson et al., 1995; Cheng et al., 1996) (Figure 3). At the second, the spinal level 
ORs are present in the dorsal horn of the spinal cord (Figure 3). Each receptor type has a 
unique distribution. MORs have a more diffuse distribution in both lamina I and II 
(Arvidsson et al., 1995), but mainly in lamina II (Ji et al., 1995). The third level at which 
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opioids modulate nociception, is the brain. The ORs are widely spread throughout the brain 
and are expressed primarily in the cortex, limbic system and brain stem (Figure 4). Thus, 
high concentrations of ORs are found in the periaqueductal gray (PAG), the locus coeruleus 
(LC) and the rostroventral medulla (RVM) (the nucleus raphe magnus (NRM) and the 
reticular formation) (Kalyuzhny et al., 1996). In most brain regions, all three OR types can be 
found, albeit in some regions higher numbers of one or the other OR are present. For 
instance, the mu opioid receptor is mostly present in the amygdala, thalamus, mesencephalon 
and some brain stem nuclei (review: Le Merrer et al., 2009). 
 
Figure 3. Localization of the mu opioid receptors in the 
spinal dorsal horn and the dorsal root ganglia (green). 1: 
dorsal horn; 2: ventral horn; 3: central canal; 4: spinal 
white matter; 5: dorsal root of spinal nerve; 6: ventral root 





Figure 4. Localization of the mu opioid receptors (MOR) 
in the brain (green). High densities of the MOR are found 
in the cerebral cortex (1), the limbic system containing the 
hippocampus (2), thalamus (3), amygdala (4) and 
hypothalamus (5), and the brainstem (6). 
 
Since MORs are located in all three of these levels, morphine exerts its analgesic action by 
modulating neurotransmission at all different levels. In the periphery and in the spinal dorsal 
horn the activation of MORs reduces the conductance of the painful stimulus (Kline and 
Wiley, 2008). Supraspinally, MOR activation triggers descending inhibitory pathways 
(review on descending control of pain: Heinricher et al., 2009). These descending pathways 
are characterized by the contribution of other neurotransmitter systems, both in the brain 
itself and in the spinal cord (review: Fields et al., 1991). Those neurotransmitters, such as 
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serotonin and GABA, are known to mediate in part the analgesic effect of morphine 
(Nemmani and Mogil, 2003). The contribution of these neurotransmitters in opioid analgesia 
was investigated by looking for insights on the morphological as well as the 
electrophysiological and behavioral aspects of these interactions. Since the present work 
focused on the serotonergic system, more specifically, the 5-HT2A receptor, only the input of 
the serotonergic system in opioid analgesia will be further discussed. 
In rodents, morphological data point to the interaction between the opioid and serotonergic 
system since there is an anatomical co-distribution of opioid and serotonergic elements. The 
raphe nuclei contain both encephalinergic – encephalin is the endogenous ligand for MORs – 
and serotonergic neurons (Moss et al., 1981; Bowker and Dilts, 1988). Bulbospinal 5-
HTergic neurons express MOR and, additionally, half of the projection neurons from the 
RVM to the spinal cord that express MOR are serotonergic (Wang and Wessendorf, 1999).   
On top of this, there is a great amount of (electro)physiological and behavioral evidence 
for the involvement of the serotonergic system in morphine induced antinociception. Two 
things are important here, first, is serotonergic involvement required for morphine analgesia? 
And second, which serotonergic receptors are involved? Both of these issues evoked quite 
some controversy and up to now no clear answer has been found to these questions. The 
involvement of 5-HT in opioid analgesia has been extensively studied. For instance, raised 5-
HT levels and increased 5-HT synthesis were found both in the spinal cord and the brain after 
systemic administration of morphine in rats and dogs (Godefroy et al., 1981; Bardon and 
Ruckebusch, 1984; Grauer et al., 1992; Tao and Auerbach, 1994 and 1995). Additionally, 
next to systemic administration, intraventricular injection of morphine also increased the 5-
HT release in the spinal cord (Jung et al., 1994). The increased amount of 5-HT in the spinal 
cord most likely originates in the higher brain nuclei since local application of morphine to 
the spinal cord had no effect on the 5-HT levels or the 5-HT turnover (Bineau-Thurotte et al., 
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1984; Vasko et al., 1984; Matos et al., 1992). Decreased levels of 5-HT in the central nervous 
system were shown to reduce morphine-induced analgesia (Vogt, 1974; Proudfit and 
Anderson, 1975; Bodnar et al., 1981; Berge et al., 1983; Millan and Colpaert, 1991a and 
1991b; Zhao et al., 2007).  
Several studies were conducted using microinjection techniques where morphine could be 
applied directly in specific brain regions. Direct administration of morphine in the NRM 
produces analgesia that is reduced by pretreatment with a 5-HT2 receptor blocker (Dickenson 
et al., 1979). Furthermore, administration of morphine directly into the PAG results in 
antinociception, mediated in part by increased spinal 5-HT levels and the activation of spinal 
5-HT1A receptors (Lin et al., 1996; Liu et al., 2002). This latter example leads to the 
involvement of specific 5-HT receptors in opioid analgesia, where it is not surprising to find 
different – and sometimes contradictory – results due to the complexity of the excitatory and 
inhibitory responses to 5-HT by the different 5-HT receptors (Millan, 1995). Reviewing these 
results would be too extensive, however, it does point towards a possibly important role of 
these receptors in opioid analgesia and/or opioid side effects. 
2. Opioids and their (side)effects 
Analgesia is the key property of opioid drugs and is the reason for the great success of 
these drugs in pain management in both humans and animals. Especially in acute severe cases 
of pain, opioids are protagonists at achieving profound pain relief. Being the prototypical 
opioid, morphine is still one of the most administered opioids and its pharmacokinetics in 
dogs have also been extensively studied.  Clinical effective morphine plasma concentrations 
in dogs are 13,92 ± 2,39 ng/mL (KuKanich et al., 2005). In that study it was also reported 
that a significant analgesic level was present for 2.8 ± 0.6 hours (KuKanich et al., 2005). In a 
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clinical setting on the other hand, morphine is usually administered every 4 hours to maintain 
proper analgesia (Lamont and Matthews, 2007). 
Due to the widespread distribution of opioid receptors and their endogenous ligands, it is 
not surprising that, next to the analgesic action of opioids, several adverse effects can occur, 
both after a short period of administration and after chronic exposure to opioids. These side 
effects will be briefly discussed in the following section. 
Acute side effects 
Acute side effects due to opioid administration occurring both in humans and animals 
include sedation (although sometimes a wanted therapeutic effect in veterinary medicine), 
nausea, vomiting, respiratory depression (rare but dangerous) and constipation. Most of these 
effects are dose-related for morphine and other MOR agonists and are clinically manageable. 
Therefore, the use of opioids has remained one of the cornerstones of acute pain management 
for decades both in human and veterinary medicine (Lamont and Mathews, 2007; WHO, 
2012a and 2012b).  
In clinical settings, nausea and vomiting occur frequently in humans and dogs following 
opioid administration (Lamont and Mathews, 2007; Porreca and Ossipov, 2009). Opioids 
induce an emetogenic effect via different mechanisms, i.e. the direct stimulation of the 
chemoreceptor trigger zone, the inhibition of gastrointestinal motility and the stimulation of 
the vestibular apparatus in the temporal lobe (Porreca and Ossipov, 2009). 
 Although the effects of opioids on cardiac output, heart rhythm and blood pressure are 
minimal, high doses of opioids can cause cardiac depression resulting in bradycardia 
(Maiante et al., 2012; Bowdle, 1998). Due to the diminished responsiveness of respiratory 
centers in the brain stem, arterial CO2 concentrations can rise, causing cerebral vasodilation 
and increased intracranial pressure. Additionally, in the case of morphine, a possible 
histamine release can provoke vasodilation and hypotension (Barke and Hough, 1993).  
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Opioid induced respiratory depression can potentially be life threatening and is caused by 
a combination of several mechanisms including peripheral and central components, i.e. 
depression of respiratory control centers. Peripherally, opioid receptors are located in the 
carotid bodies and in the vagal nerves. Additionally, opioid receptors are found on 
mechanosensory receptors located in the epithelial, submucosal, and muscular layers of the 
airways that transmit mechanical and sensory information from the lungs (review: Pattinson, 
2008). 
Problems of constipation due to opioid use are mostly seen in humans (Porreca and 
Ossipov, 2009). During the perioperative use of opioids in dogs an initial stimulation to 
defecate followed by ileus, is a typically encountered side effect (Lamont and Mathews, 
2007). The inhibition of gastrointestinal motility is caused by central and peripheral opioid 
receptors, but the effect of opioids on the myenteric plexus – thus inhibiting the intestinal 
peristaltic movement – is probably the main cause (Porreca and Ossipov, 2009). 
Chronic side effects 
Long-term use of opioids for chronic pain management is severely hindered by the 
development of three important side effects: tolerance, addiction and dependence. In research 
settings, animal models of addiction and dependence have been developed, but the clinical 
importance of these two side effects is of lesser importance in veterinary medicine compared 
to their importance in human medicine. The possibility of these side effects is however an 
important reason for physicians (both veterinary and human) to be cautious with the use of 
these otherwise very potent analgesics. Nevertheless, in cases of severe pain (e.g. cancer 
pain, both in humans and animals), the alternative analgesics such as non-steroidal anti-
inflammatory drugs are not potent enough to provide sufficient relief for these patients 
(WHO, 2012a and 2012b). The underlying mechanisms of development of these side effects 
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are not yet fully understood and better understanding these mechanisms would help in the 
search for new opioids with fewer side effects or in the search for therapeutic adjuvants that 
could help to diminish or avoid these side effects. 
Tolerance to a drug is defined as a diminished (analgesic) response to the drug or the need 
for higher doses to achieve the same effect. Morphine induces tolerance to its analgesic effect 
rather rapidly. There are several hypotheses about how tolerance develops, a diminished 
capability of inducing receptor internalization and a defective receptor desensitization and 
endocytosis are most likely the cause (review: Bailey and Connor, 2005; Berger and 
Whistler, 2010). Normally, after activation of the receptor by a ligand, receptors are rapidly 
phosphorylated by GPCR kinases (GRKs) and subsequently bound by arrestin. These events 
uncouple the MOR from G-protein, resulting in receptor desensitization. Endocytosis of the 
agonist-receptor complex follows the binding of arrestins. In the early endosome, the agonist 
unbinds, receptors are dephosphorylated and then quickly recycled to the cell surface, 
resulting in resensitization. The endogenous MOR agonist enkephalin leads to effective MOR 
internalization and thus receptor resensitization follows in a rapid manner and by analogy, the 
recovery of response to agonists as well (Figure 5A). With morphine on the other hand, this 
internalization process is compromised. In a state of tolerance, these mechanisms are 
defective, causing a deficient response to the ligand (Figure 5B) (review: Berger and 
Whistler, 2010; Williams et al., 2013).  
Other ligands and receptors have been investigated for their possible role in the 
modulation of opioid receptor internalization. Among these, co-activation of the 5-HT2A 
receptor has been shown to increase mu opioid receptor internalization (López-Giménez et 
al., 2008).  
 
 





Figure 5. The G-protein coupled receptor (GPCR) cycle. 5A: After binding of the endogenous agonist 
enkephalin, the conformation of the mu opioid receptor (MOR) is changed to its activated conformation 
that binds with the G-protein. Following activation, the MOR is phophorylated by GPCR kinases that 
desensitize the receptor and bound by β-arrestin that initiates MOR endocytosis. The MOR can then either 
be dissociated from β-arrestin, dephosporylated and recycled to the cell surface; or undergo complete 
degradation. 5B: When morphine binds to the MOR, the receptor internalization, desensitization and 
endocytosis processes are decreased and the normal GPCR cycle is compromised, leading to the complex 
phenomenon of tolerance. 
A 
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An addictive state is defined by intense drug craving and compulsive use of the drug. Drug 
addiction is a very complex phenomenon. It is thought that drugs of abuse abnormally recruit 
neuronal pathways and neurotransmitter systems responding to natural reinforcement and 
progressively alter their function. These neurotransmitter systems include the mesolimbic 
dopaminergic system that promotes reward, pleasure and compulsion and the opioid system 
that mediates pleasure (review: Koob and Nestler, 1997; Le Merrer et al., 2009). 
Additionally, drugs of abuse can induce long-lasting neuronal adaptations and a dysfunction 
of the serotonergic neurons has been observed after repeated administration of drugs of abuse 
(Salomon et al., 2006). The increased reactivity of these serotonergic neurons was prevented 
by 5-HT2A receptor antagonists, suggesting an important role for this receptor in the 
development of addiction (Salomon et al., 2006; Lanteri et al., 2008).  
Dependence is defined as an altered physiological state induced by chronic drug exposure, 
which leads to a withdrawal syndrome upon cessation of drug administration. Chronic drug 
exposure leads to cellular and molecular adaptations, among which the upregulation of the 
cAMP pathway. This is an attempt to overcome the chronic inhibition caused by the chronic 
opioid tone. Once the drug exposure is stopped, the inhibition stops as well, leading to an 
overdrive of the cAMP system. All of this leads to an overproduction of neurotransmitters, 
such as noradrenalin, which then causes withdrawal symptoms (Bailey and Connor, 2005). 
Early symptoms of withdrawal (12-30 hours after cessation of drug intake) include agitation, 
anxiety, tachycardia, hypertension, muscle aches / tremor, increased tearing, insomnia, runny 
nose, sweating and yawning. Late symptoms of withdrawal are abdominal cramping, 
diarrhea, dilated pupils, goose bumps, nausea and vomiting.  
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C. Pain modulation and brain function 
Over the last decades, functional brain imaging has provided useful information on the 
very complex mechanisms of pain transmission, perception and modulation. Two aspects of 
brain function can be studied with functional imaging: brain activity by means of cerebral 
blood flow measurement, and neurochemistry (neurotransmitter systems). Especially the 
visualization of brain regions that respond to pain with changes in brain activity, and thus 
blood flow, played a major role in advancing our knowledge of pain (Peyron et al., 2000). 
However, it is important to note that the activation of a brain region can be the result of the 
activation of an excitatory neuron or an inhibitory neuron (Sokoloff et al., 1977; Peyron et al., 
2000). This cannot be discriminated by brain activity imaging studies alone. The combination 
of brain activity studies with neurotransmitter studies is therefore of great importance. 
1. Brain function and pain 
Pain-related functional brain imaging studies typically assess the brain’s response to non-
painful stimuli compared to painful stimuli. In normal subjects this has led to a better 
understanding of the brain networks that are involved in the normal processing of pain. The 
ascending pain pathways and the supraspinal circuitry of pain transmission are to this day the 
focus of ongoing investigation and the complexity of this matter is beyond the scope of this 
work (for comprehensive reviews on this topic: Willis and Westlund, 1997; Treede et al., 
1999; Ohara et al., 2005). 
In healthy subjects undergoing an acute (experimental) painful stimulus the following 
brain regions were found to be activated in functional brain imaging studies, forming the so-
called pain matrix (Legrain et al., 2011): insular cortex, somatosensory cortices (S1 and S2), 
anterior cingulate cortex (ACC), prefrontal and parietal cortex, thalamus and brainstem 
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structures (PAG, reticular formation) (Peyron et al., 2000; Casey et al., 1996; Casey et al., 
2000). These areas have been shown to process different features of pain (review: Treede et 
al., 1999; Peyron et al., 2000; Ohara et al., 2005). In short, the sensory-discriminative aspects 
of pain are processed by the thalamus, both somatosensory areas and the insular cortex. The 
thalamus is additionally thought to play a role in the arousal reaction to pain. The role of the 
ACC in pain processing is rather complex as it is involved in the emotional and cognitive-
attentional aspects of pain (Peyron et al., 2000). The attentional component of pain 
perception is also processed in the prefrontal and parietal cortices. The activation of 
brainstem structures by pain either reflects an arousal reaction to pain or the activation of 
descending pain inhibitory pathways (Peyron et al., 2000).  
The difficulty of interpreting results from studies in pain patients, lies in the great diversity 
in pain itself. Not only the duration of pain is a factor, the severity and the cause of pain can 
also vary from case to case. Next to the considerable variation from subject to subject, due to 
the complexity of pain perception and modulation, even intra-individual variations can occur. 
All these factors make it difficult to create homogeneous subject groups.  
Chronic pain induces neuroplastic changes within the nociceptive system, the so-called 
peripheral and central sensitization that occur after a chronic noxious stimulus. Tissue 
damage and inflammation induce sensitization of the peripheral nerve endings thus 
altering/increasing the responsiveness of the peripheral nociceptors, this is peripheral 
sensitization (Raja et al., 1988; Muir and Woolf, 2001). This increased nociceptive signaling 
can induce changes in the synaptic transmission in the spinal cord, this is central sensitization 
(Woolf, 1996). Both of these mechanisms can cause augmented nociceptive input to the 
brain, which can cause functional and structural alternations of the pain processing pathways 
in the brain. This in turn is reflected by altered brain activity patterns in brain imaging 
studies. Discussing this complex matter (neuroplasticity and additional differences depending 
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on the type of chronic pain) is beyond the scope of the present work. However, in brief, 
abnormal over-activation of the lateral pain system (thalamus and parietal cortex) is 
commonly seen, whereas the responses in the ACC, insula, S1 and prefrontal regions appear 
to be more complex (Peyron et al., 2000; Seifert and Maihöfner, 2011). 
2. Brain function and opioids 
The distribution of opioid receptors in the brain clearly indicates that opioids can modulate 
brain function. As mentioned in the previous part, one of the ways to investigate brain 
function is by functional imaging of regional cerebral blood flow. Not surprisingly, the 
influence of opioids on brain function has been studied extensively, mainly with the focus on 
chronic pain and drug addiction and dependence due to long term opioid (ab-)use.  
A first remark on opioids and cerebral blood flow regards the impact of these drugs on 
global cerebral blood flow. Since opioids can alter respiration, a hypercapnic-induced 
increase in global cerebral blood flow can occur (Pattinson et al., 2007; MacIntosh et al., 
2008). This needs to be taken into account when interpreting imaging results and, if possible, 
controlling the respiratory rate (and PaCO2 values) is advised in subjects under anesthesia. 
This global alteration of blood flow has, however, no correlation to functional brain activity, 
which is reflected by regional changes in blood flow. 
In functional brain imaging studies of healthy subjects receiving only a mu agonist opioid, 
increases in regional cerebral blood flow were observed in the ACC, the brainstem (including 
the PAG), the prefrontal and parietal cortex, and the cerebellum, as well as decreased brain 
activity in the thalamus and posterior cingulate cortex (Firestone et al., 1996; Adler et al., 
1997; Casey et al., 2000; Wagner et al., 2001; Khalili-Mahani et al., 2012). In combination 
with a painful stimulus, opioids tend to decrease the pain-evoked cerebral blood flow 
augmentation in both cortical and subcortical regions involved in pain processing and/or 
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modulation. This is in spite of the fact that when given alone, opioids activate certain of these 
regions (Casey et al., 2000; Wagner et al., 2007). This has been reported in several rodent 
models of experimental pain as well (review: Thompson and Bushnell, 2012). Additionally, 
Wagner and colleagues found that an increasing dosage of remifentanil would increase brain 
activity in regions involved in the descending inhibition of pain, whereas it would decrease 
brain activity in regions involved in pain perception (Wagner et al., 2007). However, during 
combined administration of fentanyl and a painful stimulus, an increased pain-related brain 
activation of the supplementary motor area and the prefrontal cortex was observed, possibly 
explained by the blockade of motor function and the interference in the affective-
motivational aspect of pain processing by fentanyl (Adler et al., 1997).  
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D. Pain modulation and the serotonergic system 
As mentioned in the previous part, the modulation of pain by opioids relies in part on 
different neurotransmitter systems and interactions between them. One of these 
neurotransmitter systems is the serotonergic system. The monoamine serotonin (5-
hydroxytryptamine, 5-HT) is a neurotransmitter widely distributed in the nervous system, 
both in the periphery and centrally. It is thought to play a role in many varying functions 
throughout the body, such as mood, platelet aggregation, vascular tone and intestinal motility 
(review: Mohammad-Zadeh et al., 2008). In human medicine there has been a lot of interest 
in the involvement of serotonin in various neuropsychiatric diseases and their treatment (e.g. 
Alzheimer disease, Parkinson disease, anxiety disorders, migraine, depression…) (Graeff et 
al., 1996; Nikolaus et al., 2009a and 2009b). A role in pain modulation is another important 
action of 5-HT as a neurotransmitter in the central nervous system. Unlike opioids, the role of 
5-HT in pain modulation is not straightforward. Depending on the receptor type and the site 
of action (as well as the interaction with other neurotransmitter systems) 5-HT was found to 
have inhibitory or excitatory effects, resp. leading to the attenuation or the enhancement of 
nociception/pain transmission and sensation (Millan, 1995; Aghajanian and Marek, 1997; 
Marek and Aghajanian, 1998a; Aghajanian and Marek, 1999; Millan, 2002; Suzuki et al., 
2004; Yoshimura and Furue, 2006). However, it can be stated that the overall effect of 5-HT 
is inhibitory regarding neurotransmission (Grudt et al., 1995). 
1. 5-HT receptor subtypes 
There are 7 known 5-HT receptor types or families, i.e. from the 5-HT1 to the 5-HT7 
receptor. Some of these receptors can be subdivided into different subtypes, e.g. 5-HT1A, 1B, 
1C and 5-HT2A and 2C (Hoyer et al., 1994). Not all of these receptor (sub)types are 
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important for nociception, in fact only the receptors belonging to the 5-HT1, 5-HT2, 5-HT3, 
5-HT4 and 5-HT7 receptor families are thought to play a role in pain modulation (Millan, 
2002). All 5-HT receptors, except the 5-HT3 receptor, are GPCRs, although they differ in the 
effector system activated. 5-HT1 receptors (with the exception of 5-HT1C) are negatively 
coupled to adenylate cyclase, whereas 5-HT4 and 5-HT1C receptors are coupled to adenylate 
cyclase in an excitatory fashion. 5-HT2 receptors on the other hand are coupled to the 
phosphatidylinositol pathway, activating phospholipase C, but also activating phospholipase 
A2 (Brodde, 1990; Felder et al., 1990; Hoyer et al., 1994; Berg et al., 1994; Millan, 2002). 5-
HT2A receptors are located both pre- and postsynaptically (Doly et al., 2004). The 5-HT3 
receptor is a ligand-gated ion channel and binding to it results in neuronal depolarization and 
an increase in free intracellular Ca++ (review: Reeves and Lummis, 2002).  
The source of endogenous 5-HT are the serotonergic neurons that are widely distributed 
throughout the brain. The great majority of serotonergic cells is located in the different raphe 
nuclei and the reticular formation (Holmes et al., 1994; Leger et al., 2001; Hornung, 2003). 
The dorsal and the median raphe nucleus contain most of the 5-HTergic neurons, followed by 
the nucleus raphe major, obscurus and pallidus (Takeuchi and Sano, 1982; Kojima et al., 
1983; Kapadia et al., 1985; Duann et al., 1989; Bjarkam et al., 1997; Gao and Mason, 2001). 
Two major projections emerge from these nuclei: to the forebrain and to the brainstem and 
spinal cord (Kazakov et al., 1993; Hornung, 2003). For pain modulation, projections to the 
spinal cord are particularly important, since 5-HT exerts an antinociceptive action at a spinal 
level (Fürst, 1999; Braz and Basbaum, 2008).  
2. 5-HT2A receptor 
As mentioned previously, the action of 5-HT is antinociceptive or pronociceptive 
depending on the receptor type, administration route and pain modality tested (Millan, 2002). 
The involvement of the 5-HT2A receptor in nociception has been demonstrated in 
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neuropathic and sustained inflammatory pain states, where administration of 5-HT2A 
antagonists reduced hyperalgesia (Nitanda et al., 2005; Van Steenwinckel et al., 2008; 
Thibault et al., 2008). The 5-HT2A receptor is also thought to be involved in the cognitive 
modulation and the cognitive-evaluative aspects of pain processing due to its location in 
regions involved in these aspects of pain modulation, i.e. the orbitofrontal, frontal and 
prefrontal cortex (Kupers et al., 2009).  
Next to the role of 5-HT2A receptors in nociception, the focus of research on this receptor 
was put on its role in neuropsychiatric disorders. Indeed, it has been shown on numerous 
occasions that the 5-HT2A receptor is involved in either the etiogenesis or the treatment of 
several mood disorders, such as depression, aggression and anxiety (Celada et al., 2003; 
Peremans et al., 2003b; Peremans et al., 2005; Nic Dhonnchadha et al., 2003; Meyer et al., 
2008; Vermeire et al., 2009). Moreover, it also has been shown to be involved in other 
neurological diseases such as Parkinson disease, schizophrenia and insomnia (Abbas and 
Roth, 2008; Li et al., 2010). This has mainly been of interest in human medicine since these 
diseases are still not fully understood and adequate treatment is often difficult to find. In the 
past decade however, research involving mood disorders in small animals has progressed as 
well. Problems of aggression and anxiety in dogs are for instance a growing point of interest 
in veterinary research. Research on these specific problems has been conducted at our facility 
over the past years and a link between these mood disorders and the 5-HT2A receptors has 
been found, similar to that in humans (Vermeire et al., 2009). This is important for two 
reasons: first, it is important for those dogs and their environment to better understand and 
treat behaviour problems in dogs; second, the dog can be used as a suitable research model 
for these diseases since aggression and anxiety occur naturally in dogs, thus providing a 
better model compared to induced models in other laboratory animals.  
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E. Methods for the present work: SPECT 
Functional imaging of the central nervous system is of great importance, not only to better 
understand the very complex brain physiology, but also to investigate the underlying causes 
of various brain pathologies and to gain an insight in the mode of action of centrally acting 
drugs like opioids. In functional brain imaging, there are two types of studies, namely, studies 
regarding specific neurotransmitter systems: neuroreceptor binding studies, and the 
visualization of brain activity, which was discussed earlier. Both are equally important in 
order to get a full picture of how drugs work and how diseases develop and can be interesting 
tools to assess ongoing therapy.  
Single photon emission computed tomography (SPECT) is one of the conventional 
functional nuclear imaging techniques. In human medicine, it has proved most useful in the 
characterization of various diseases, such as Alzheimer’s disease, Parkinson disease, 
epilepsy, psychiatric disease, brain tumors and degenerative diseases. Brain SPECT imaging 
in small animals has mainly been used in research settings where, beside its value in studying 
animal models, it has contributed to understanding and underpinning the biological base for 
behavior disorders from a veterinary medicine point of view (Peremans et al., 2003b; 
Vermeire et al., 2009). Next to the use of brain SPECT imaging for disease research, brain 
SPECT can also be used to investigate the mechanism of action of drugs acting on the central 
nervous system. 
1. SPECT Technique 
Nuclear functional brain imaging has been an important tool for the investigation of 
neurological processes. SPECT is an imaging technique used to visualize both neuronal 
function and components of neurotransmitter systems (receptors, transporters) in vivo in a 
direct and non-invasive manner using radioactive ligands. This modality is considered to 
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date, one of the most sensitive modalities to investigate in vivo interactions with 
neurotransmitters and receptors/transporters (Ametamey et al., 2008). 
In short, SPECT is an imaging procedure in which a radioactive isotope (123I, 99mTc, 131I, 
…) bound to a biochemical compound is administered to a subject. As the isotope decays, it 
emits photons from the body that are detected and recorded by a camera, thus providing an 
image of the distribution of the radioligand in the body. The major advantage of these 
radioligands is that the required amount of radiopharmaceutical is subpharmacological, 
meaning that specific neurotransmitter systems can be visualized without being harmful for 
the subject. Once the radiopharmaceutical enters the blood stream, it is distributed through 
the body organs (brain, liver, kidney, heart and the peripheral vascular system) and, 
according to each organ’s affinity for the particular compound, a specific distribution pattern 
will become visible.  
2. Small animal brain imaging 
As mentioned, the use of SPECT imaging in small animals has been valuable not only for 
diseases occurring in these animals, but also for its use as a model for human medicine. 
Research at our facility has been focusing over the last decades on both aspects. Evidently, 
perfecting the SPECT technique for its use in small animals was one of the first steps to be 
accomplished. Using small animals in brain imaging studies comes with some advantages: 
(1) the possibility to perform longitudinal brain imaging studies (shorter life spans), (2) ex 
vivo analysis of the brain can possibly be performed after the imaging study, and (3) new 
drugs can be assessed prior to approval for human use (review: Thompson and Bushnell, 
2012).  
Unfortunately, there are also some limitations associated with the use of animals. First, 
and most importantly, is the species difference. This is reflected in several ways: differences 
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in anatomy, physiology and pathology. Adapting collimator size, developing new software 
for image reconstruction and creating a canine/feline brain map database were solutions for 
the anatomy difference. After this, the difference in physiology had to be investigated. 
Tracers that are commonly used in humans are not necessarily suitable in small animals. 
Furthermore, differences in permeability of the blood brain barrier can occur between animal 
species as well. Therefore, feasibility studies first need to be conducted in order to assess the 
use of each radioligand in different animal species. Finally, using animals as models for 
human disease has its challenges since common diseases in humans, do not necessarily occur 
in animals. Inducing these diseases is one way of solving the problem, however, naturally 
occurring diseases are more likely to provide accurate results. In this light, canine behavioral 
problems, such as aggression and anxiety, are grateful to work with since they resemble 
certain neuropsychiatric diseases in humans.  
Another important concern when performing small animal brain imaging is the necessity 
of immobilization of the animal. This requires the use of anesthetics that can have an 
influence on the central nervous system and could interfere with the studied neurotransmitter 
system and/or the brain perfusion. In order to eliminate this confounding factor, comparative 
studies are necessary. So far, no major objections can be made anesthesia-wise when looking 
at the results from our research group, as long as the used anesthesia protocols are kept 
constant between studies to ensure optimal comparison and as long as the use of anesthetics 
is taken into account when interpreting the results.  
3. Tracers 
The present work has focused on the effects of an opioid, morphine, on the brain perfusion 
and on the 5-HT2A receptor system in dogs. To assess the influence of morphine on the 
regional cerebral blood flow, two 99mTc-labelled tracers were used: 99mTc-ECD 
(Ethylcysteinate dimer) and 99mTc-HMPAO (Hexamethylpropylene amine oxime).  For the 
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evaluation of the influence of morphine on the 5-HT2A receptor system, 123I-labelled R91150 
was used. 
Cerebral blood flow: 99mTc-ECD and 99mTc-HMPAO 
Regional brain perfusion is known to correlate with brain activity, making these tracers 
markers for regional brain activity next to markers for regional perfusion (Sokoloff et al., 
1977; Gerrits et al., 1998). Indeed, higher activity means a higher metabolization rate, 
requiring higher supplies of oxygen, precursors for protein synthesis and glucose, and 
therefore blood supply.  
Even though the first-pass extraction in brain tissue of both radioligands is high, each 
radioligand has a different retention mechanism. Both tracers undergo intracellular 
metabolization from a lipophilic form that readily passes the blood-brain-barrier, to a 
hydrophilic form that is trapped within the cell. However, this trapping mechanism differs 
between the two tracers. 99mTc-ECD is enzymatically transformed by intracellular esterases, 
whereas transformation of 99mTc-HMPAO is mainly thought to depend on the glutathione 
content and the redox equilibrium in the cell (Jacquier-Sarlin et al., 1996a and 1996b). In 
humans, this difference in retention mechanism has been suggested to be a possible cause for 
differences in regional distribution between both tracers.  
99mTc-ECD has been used in dogs in several studies (Peremans et al., 2001; Peremans et 
al., 2003b; Martlé et al., 2009; Waelbers et al., 2011 and 2012), however, due to unforeseen 
technical reasons, the production of 99mTc-ECD was stopped, therefore creating the need to 
explore other regional cerebral blood flow tracers, such as 99mTc-HMPAO. 99mTc-HMPAO is 
used frequently in humans, but information on the use of this tracer in dogs is scarce (Bok et 
al., 1987; Susskind et al., 1996). Hence, a first study was conducted to assess its suitability 
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for regional cerebral blood flow evaluation in dogs as well as to compare 99mTc-ECD and 
99mTc-HMPAO.  
5-HT2A receptor system: 123I-R91150 
To evaluate the influence of morphine on the 5-HT2A receptor system, the 123I-labelled 
R91150 tracer was used. This tracer has been used in dogs previously (Peremans et al., 
2002a, 2002b and 2003a), including in studies involving canine aggression and anxiety 
(Peremans et al., 2003b and 2005; Vermeire et al., 2009). 
123I-R91150 is synthesized by electrophilic radioiodination on the 5-position of the 
methoxybenzamide group of R91150, followed by purification with high-performance liquid 
chromatography. The radioligand is a 5-HT2A antagonist with high affinity (Kd = 0.11 nM) 
and selectivity for the 5-HT2A receptor. The selectivity of the ligand for 5-HT2A receptors 
with regard to other neurotransmitter receptors such as other 5-HT receptors, including 5-
HT2C and 5-HT1A, dopamine receptors, adrenergic receptors and histamine receptors is at 
least a factor 50. The tracer is displaceable with ketanserin, a 5-HT2 antagonist and has been 
previously shown to be suitable for use in dogs (Mertens et al., 1994, Peremans et al., 2002a; 
Catafau et al., 2006).  
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To assess the regional cerebral blood flow the use of functional brain imaging, in this case 
SPECT, has been very useful. In human medicine two radiolabelled cerebral blood flow 
tracers are commonly used: 99mTc-ECD (Ethyl cysteinate dimer) and 99mTc-HMPAO 
(Hexamethylpropylene amine oxime). Even though both are equally valuable for regional 
cerebral blood flow evaluation, differences in distribution patterns between both tracers have 
been observed. In veterinary medicine 99mTc-ECD has been the most frequently used cerebral 
blood flow tracer and comparison between 99mTc-ECD and 99mTc-HMPAO is lacking. 
Therefore the first aim of this doctoral thesis was to assess the use of 99mTc-HMPAO in dogs 
and the comparison with 99mTc-ECD. 
Evaluation of regional cerebral blood flow is very valuable to gain insights into the mode 
of action of certain drugs with a supraspinal action. Analgesics like opioids are particularly 
interesting since they are still the most potent analgesics and are frequently used despite their 
severe side effects. Better understanding their mode of action could therefore improve their 
use and possibly help in the search for new and improved analgesics. The second aim of this 
doctoral thesis was therefore to evaluate the effect of a prototypical opioid, morphine, on the 
regional cerebral blood flow with the functional brain imaging technique SPECT. In a 
clinical setting analgesia is often required for longer periods and therefore the third aim was 
to assess the influence of a prolonged administration of morphine, consisting of 10 days of 
oral morphine, on the regional cerebral blood flow.  
Opioid analgesics are known to exert their analgesic effect in part through the interaction 
with other neurotransmitter systems, such as the serotonergic system. The serotonergic 
system is not only important for the analgesic action of opioids, in this case morphine, it is 
also believed to play a role in the side effects of opioids. Conversely, opioids have been 
attributed a potentially antidepressant effect, probably due in part to this interaction with the 
serotonergic system. One 5-HT receptor has been shown to be involved in all these aspects, 
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namely the 5-HT2A receptor which has been a central point of interest in mood disorder 
research. Functional imaging of this receptor by means of SPECT has been previously 
validated in dogs. The fourth aim of this doctoral study was to assess the effect of a single 
bolus of morphine on the canine cerebral 5-HT2A receptor system. As mentioned in the 
previous paragraph, analgesia – and certainly mood disorder therapy – require treatment over 
a prolonged period. Therefore, we also investigated the 5-HT2A receptor binding after a 
prolonged exposure to morphine, which was the fifth aim of this doctoral study. 
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A. Abstract  
Two 99mTc-labelled single photon emission computed tomography (SPECT) cerebral 
blood flow tracers - ethylcysteinate dimer (ECD) and hexamethylpropylene amine oxime 
(HMPAO) - are commonly used in human medicine and have been used previously in dogs, 
but intra-subject comparison of both tracers in dogs is lacking. Therefore, this study 
investigated whether regional distribution differences between both tracers occur in dogs as is 
reported in humans.  
Methods: Eight beagles underwent two SPECT examinations first with 99mTc-ECD and 
followed by 99mTc-HMPAO. SPECT scanning was performed with a triple head gamma 
camera equipped with ultrahigh resolution parallel hole collimators. Images were 
reconstructed using filtered backprojection with a Butterworth filter. Emission data were 
fitted to a template permitting semi-quantification using predefined regions or volumes of 
interest (VOI). For each VOI, perfusion indices were calculated by normalizing the regional 
counts per voxel to total brain counts per voxel. The obtained perfusion indices for each 
region for both tracers were compared with a paired Student’s T-test.  
Results: Significant regional differences between both tracers were seen in the subcortical 
region and to a lesser extent in the cerebellum.  
Conclusions: Both tracers can be used to visualize regional cerebral blood flow in dogs, 
however, due to the observed regional differences, they are not entirely interchangeable. 
  




Progress in functional brain imaging in dogs is of great importance since these types of 
brain imaging contribute to detecting functional brain dysfunctions, rather than anatomical 
abnormalities. This is valuable in the case of canine behavioral problems like anxiety and 
aggression, and some cases of epilepsy (Peremans et al., 2003b; Martlé et al., 2009; Vermeire 
et al., 2009). Using diffusible radiolabelled tracers, regional cerebral blood flow (rCBF) can 
be measured with single photon emission computed tomography (SPECT). Frequently used 
radioligands include 99mTc-ECD (ethylcysteinate dimer) and 99mTc-HMPAO 
(hexamethylpropylene amine oxime), both commonly used in investigations of 
neuropsychiatric disorders in human medicine (Kapucu et al., 2009). SPECT is, next to 
positron emission tomography (PET), a nuclear functional imaging modality that permits the 
visualization of different neurotransmitter systems in vivo in a non-invasive manner. The 
major advantages of SPECT over PET are that it is less expensive, more accessible and better 
suited for the use in animals due to the longer half-lives of the isotopes that permit a longer 
injection-acquisition interval. In human medicine, the use of SPECT as a diagnostic tool and 
research modality is widespread (Kapucu et al., 2009). In veterinary medicine, its use is 
mostly applied in research studies focusing either on animal disease or on the animal as a 
model for human disease, including research on behavioral problems, epilepsy and the mode 
of action of several drugs (Peremans et al., 2003b; Martlé et al., 2009; Vermeire et al., 2009; 
Waelbers et al., 2011). 
Even though the first-pass extraction in brain tissue of both radioligands is high, each 
radioligand has a different retention mechanism. Both tracers undergo intracellular 
metabolization from a lipophilic form that readily passes the blood-brain-barrier, to a 
hydrophilic form that is trapped within the cell. However, this trapping mechanism differs 
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between the two tracers. 99mTc-ECD is enzymatically transformed by intracellular esterases, 
whereas transformation of 99mTc-HMPAO is mainly thought to depend on the glutathione 
content and the redox equilibrium in the cell (Jacquier-Sarlin et al., 1996a and 1996b). The 
different retention mechanism has been suggested to be a possible cause for differences in 
regional distribution between both tracers (Koyama et al., 1997; Oku et al., 1997; Patterson et 
al., 1997; Siennicki-Lantz et al., 1999).  
In human medicine, many investigators have compared the differences between 99mTc-
ECD and 99mTc-HMPAO in terms of image quality and pharmacokinetics and as a result, 
differences in rCBF between both tracers were also investigated and revealed regional 
distribution differences between both tracers in healthy volunteers and in patients with 
neurological disease (Koyama et al., 1997; Oku et al., 1997; Patterson et al., 1997; Asenbaum 
et al., 1998; Siennicki-Lantz et al., 1999; Hyun et al., 2001; Ito et al., 2006). In dogs however, 
both tracers have not yet been compared. Investigating whether the differences seen in 
humans occur in dogs as well, could contribute to a better rCBF evaluation with either one of 
these neuroperfusion tracers in dogs. The aim of this study was therefore to compare rCBF 
evaluation with 99mTc-ECD and 99mTc-HMPAO in dogs. 
C. Materials and Methods 
1. Animals 
The study was approved by the Ghent University Ethical Committee (EC 2011-130). All 
guidelines for animal welfare, imposed by the Ethical Committee, were respected. Eight 
female neutered purpose bred Beagle dogs (age 5.11 ± 0.34 years, weight 8.86 ± 0.88 kg 
(mean ± standard deviation, SD)) were used for this study. None of the dogs had a history of 
major disease or neurological disorder. 
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2. Study Design 
To evaluate the rCBF, SPECT scans were conducted using 99mTc-ECD (Neurolite®, 
Bristol-Myers Squibb Medical Imaging) and 99mTc-HMPAO (Ceretec®, GE Healthcare), both 
prepared according to the manufacturer’s instructions. The first scan was conducted after an 
intravenous (IV) injection of 747.91 ± 30.22 MBq 99mTc-ECD. The second scan was 
performed after an IV injection of 358.95 ± 7.08 MBq 99mTc-HMPAO. All 8 dogs were 
scanned with both radioligands in a non-randomized order with a time interval of 6 months.  
3. Anesthetic Protocol 
Anesthesia is required for SPECT scanning in animals and all scans were performed with 
the same anesthetic protocol. Premedication (intramuscular dexmedetomidine 375 µg/m² 
body surface area, Dexdomitor®, Orion Corporation, Espoo, Finland) was administered once 
the plateau was reached for each tracer, i.e. 15 min post tracer injection for 99mTc-ECD and 
10 min post 99mTc-HMPAO injection (Susskind et al., 1996; Waelbers et al., 2012). 
Anesthesia was induced by propofol (1.74 ± 0.51 mg/kg intravenously, Propovet®, Abbott 
Laboratories, Queenborough, United Kingdom) and maintained with isoflurane (Isoflo®, 
Abbott Laboratories) in oxygen. In order to limit the influence of the PaCO2 on cerebral 
perfusion, the dogs were mechanically ventilated during anesthesia to preserve eucapnia, i.e. 
end tidal CO2 within 35-45 mmHg. 
4. Image Acquisition 
The dogs were positioned in ventral recumbency with the head stabilized in a preformed 
cushion, to prevent individual positioning artifacts. Camera and table positioning were then 
recorded to ensure optimal intra-dog comparisons. The detectors of the triple headed camera 
were positioned as closely to the dog’s head as possible. Image acquisition was started 10 
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minutes after induction of anesthesia, i.e. 40 min after tracer injection for 99mTc-ECD and 35 
min after tracer injection for 99mTc-HMPAO. The SPECT scans were performed using a triple 
head gamma camera (Triad Trionix, Twinsburg, OH, USA) equipped with ultrahigh 
resolution parallel hole collimators (tomographic resolution, 8 mm full width half maximum). 
For each acquisition, 120 projection images were obtained on a 128x128 matrix using a step-
and-shoot mode (3° steps). Pixel size was 1.72 mm. To make up for the difference in injected 
activity between both tracers, different scanning times were used, i.e. 10 s per step for 99mTc-
ECD and 15 s per step for 99mTc-HMPAO. This resulted in a total scanning time of 20 min 
for 99mTc-ECD and 30 min for 99mTc-HMPAO. 
5. Image Processing 
The acquired images need reconstruction which was performed by using filtered back 
projection and a Butterworth filter (cut-off 1.6 cycles/cm, order 5). 
After this, the emission data were fitted to a template using BRASS software (Brain 
Registration and Automated SPECT Semiquantification, Nuclear Diagnostics, Stockholm, 
Sweden) that allows scaling, rotating, and translating of the acquired images in all 3 
dimensions. This software was initially developed for humans but the template and regions 
were created in house for use in dogs (Peremans et al., 2003b). The template provides the 
necessary anatomical references and consists of a predefined region map with the following 
volumes-of-interest (VOI): right and left frontal, temporal, parietal and occipital cortices, and 
subcortical and cerebellar regions. Data from SPECT scans can be semi-quantified with this 
template by normalizing the counts per pixel in a certain VOI to the counts per pixel of the 
entire brain (sum of all VOIs). Accordingly, perfusion indices of the different VOIs were 
calculated as the mean count per voxel in each VOI normalized to the mean total count per 
total voxel. Normalizing the regional activity to total brain activity has the additional 
advantage of accounting for the difference in injected radioactivity since the amount of tracer 
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will be distributed in an equal way over the different regions and the mean counts will 
increase equally in all regions. 
Asymmetry indices (AI) were also compared for the different VOIs, as well as for the 
right and left hemisphere as a whole. AIs were determined as follows: [(perfusion index of 
the right VOI or hemisphere – perfusion index of the left VOI or hemisphere) / (perfusion 
index of the right VOI or hemisphere + perfusion index of the left VOI or hemisphere)] x 
200. Finally, a cortical-subcortical index was calculated as (perfusion index of all cortical 
regions) / (perfusion index of the subcortical region).  
6. Statistical analysis 
Statistical analysis was performed by the first author using commercial software (SPSS 
Statistics 19, SPSS Inc, USA). The means ± SD of the perfusion indices, asymmetry indices 
and cortical-subcortical ratios were calculated. Normally distributed perfusion index means 
were compared using the paired Student’s T-test. Asymmetry indices and cortical-subcortical 
ratios were compared using the Wilcoxon signed ranks test. Statistical significance was set at 
P < 0.05. Additionally, correction for multiple comparisons was applied using Bonferroni 
correction (P < 0.005). 
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D. Results 
Perfusion indices (mean ± SD) and P-values for all brain regions using 99mTc-ECD and 
99mTc-HMPAO are summarized in Table 1.  
Table 1. Perfusion indices for ten brain volumes of interest using 99mTc-ECD and 99mTc-HMPAO in eight 
healthy dogs (mean ± SD).  
Brain region 99mTc-ECD 99mTc-HMPAO P 
Left frontal 1.12 ± 0.05 1.14 ± 0.04 0.28 
Right frontal 1.12 ± 0.02 1.14 ± 0.06 0.46 
Left temporal 0.86 ± 0.02 0.88 ± 0.04 0.16 
Right temporal 0.85 ± 0.05 0.86 ± 0.04 0.52 
Left parietal 1.12 ± 0.07 1.12 ± 0.05 0.98 
Right parietal 1.11 ± 0.04 1.09 ± 0.05 0.29 
Left occipital 1.08 ± 0.07 1.09 ± 0.07 0.72 
Right  occipital 1.07 ± 0.05 1.09 ± 0.07 0.41 
Subcortical 1.24 ± 0.03 1.17 ± 0.02 0.001* 
Cerebellum 1.05 ± 0.02 1.09 ± 0.04 0.03 
* P < 0.005 after Bonferroni correction for multiple comparisons. 
The use of 99mTc-ECD resulted in higher perfusion indices in the subcortical region 
compared to 99mTc-HMPAO (P < 0.005). Though no longer significant after correcting for 
multplie comparisons, perfusion indices in the cerebellum were lower in the 99mTc-ECD data 
compared to the 99mTc-HMPAO data. These differences are illustrated in Figure 1.  







Figure 1. Sagittal acquisitions obtained with 
99mTc-ECD (A) and 99mTc-HMPAO (B). Higher 
99mTc-ECD uptake was found in the subcortical 
region (1), whereas the cerebellum (2) showed 
higher 99mTc-HMPAO uptake. 
 
Interhemispheric asymmetry was absent for both tracers and AIs for the separate cortical 
regions did not differ between both tracers (Table 2). The cortical-subcortical ratio was 
significantly higher for the 99mTc-HMPAO data (Table 2 and Figure 2).  
Table 2. Asymmetry indices for the five cerebral cortical brain regions and the cortical-subcortical ratios 
obtained with 99mTc-ECD and 99mTc-HMPAO in eight healthy dogs (mean ± SD).  
Variable 99mTc-ECD 99mTc-HMPAO P 
AI frontal -0.24 ± 4.47 -0.59 ± 5.54 0.89 
AI temporal -1.30 ± 4.84 -2.80 ± 5.12 0.58 
AI parietal -1.39 ± 6.63 -3.19 ± 4.29 0.33 
AI occipital -0.66 ± 4.32 -0.14 ± 6.34 0.67 
AI hemispheres -0.81 ± 4.20 -1.57 ± 4.88 0.89 
CSC 82.15 ± 2.50 87.72 ± 0.77 0.01 
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Figure 2. Dorsal acquisitions obtained with 
99mTc-ECD (A) and 99mTc-HMPAO (B). A 
higher cortical-subcortical ratio was found for 
99mTc-HMPAO, which can be visualized as 
better cortical-subcortical contrast. 
 
E. Discussion 
This study compared regional 99mTc-ECD and 99mTc-HMPAO uptake in the normal canine 
brain. The data demonstrated a difference in regional uptake between both tracers in the 
subcortical region and to a lesser extent in the cerebellum. 
Reports on rCBF in dogs mainly used 99mTc-ECD as a tracer (Peremans et al., 2001). 
Indeed, next to distribution studies in healthy dogs, the use of 99mTc-ECD has also been 
documented in research on behavioral problems such as anxiety and aggression and on the 
influence of several anesthetic protocols on brain perfusion (Peremans et al., 2003b; 
Vermeire te al., 2009; Waelbers et al., 2011). In contrast, only few studies report on the use 
of 99mTc-HMPAO in dogs for rCBF evaluation, mainly focusing on the tracer kinetics (Bok et 
al., 1987; Susskind et al., 1996).  According to those studies, some drawbacks of 99mTc-
HMPAO include a slower blood clearance, resulting in a poorer brain-to-background 
contrast, a higher extracerebral uptake and higher brain-to-blood back diffusion (Bok et al., 
1987; Susskind et al., 1996). Therefore, 99mTc-HMPAO image quality is considered to be 
inferior to 99mTc-ECD images. In the present study, similar to 99mTc-ECD, the highest 
perfusion index was found in the subcortical region with 99mTc-HMPAO as well (Peremans et 
al., 2001). This is in agreement with the high thalamic 99mTc-HMPAO uptake found in dogs 
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(Susskind et al., 1996). High cerebral blood flow was also seen in the frontal cortex for both 
tracers. This is not in agreement with the study on normal brain perfusion measured with 
99mTc-ECD where frontal perfusion indices were not as high as those seen in the present 
study (Peremans et al., 2001). An explanation for this discrepancy may be the uniform 
attenuation correction applied on the data in the latter study, possibly overcorrecting the 
activity in the less attenuated frontal cortical areas. 
In this study we demonstrated that, similar to humans, differences in regional uptake 
between 99mTc-ECD and 99mTc-HMPAO occur in dogs. Remarkably, we found a higher 
cortical-subcortical ratio for the 99mTc-HMPAO scans compared to the 99mTc-ECD scans. 
This relatively higher accumulation of 99mTc-HMPAO in the cortical regions seems to be in 
contrast to the findings in human studies where, globally, 99mTc-ECD gave better 
visualization of cortical regions and 99mTc-HMPAO of subcortical structures (Koyama et al., 
1997; Oku et al., 1997; Patterson et al., 1997; Siennicki-Lantz et al., 1999; Ito et al., 2006). 
We also found a higher uptake of 99mTc-HMPAO in the cerebellum compared to 99mTc-
ECD. This is in agreement with several studies in humans (Koyama et al., 1997; Oku et al., 
1997; Patterson et al., 1997). As the cerebellum is commonly used as a reference region for 
semiquantification purposes, this difference in cerebellar uptake is very important and 
semiquantification using the entire brain, instead of the cerebellum, as a reference region is 
preferable.  
Several hypotheses have been proposed to explain the observed differences in perfusion 
patterns between 99mTc-ECD and 99mTc-HMPAO. Most of these hypotheses depart from 
different pharmacokinetic properties, which are thought to be the main cause for the observed 
discrepancies (Oku et al., 1997; Asenbaum et al., 1998; Hyun et al., 2001). First, both tracers 
have a different trapping mechanism. 99mTc-ECD trapping depends on esterase activity, 
whereas 99mTc-HMPAO trapping depends on glutathione availability and redox equilibrium 
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(Jacquier-Sarlin et al., 1996a and 1996b). Furthermore, it has been suggested that 99mTc-ECD 
was more sensitive to the regional metabolic rate than 99mTc-HMPAO (Oku et al., 1997). 
Differences in regional metabolism could therefore influence the accumulation of 99mTc-ECD 
more than 99mTc-HMPAO. Finally, 99mTc-ECD shows a lower back diffusion from brain 
tissue to the blood and possesses a higher retained fraction in the brain, compared to 99mTc-
HMPAO that has a significant cerebral blood flow-dependent back diffusion (Andersen et al., 
1988; Lassen et al., 1988; Murase et al., 1992; Friberg et al., 1994; Shishido et al., 1994; 
Yonekura et al., 1994). 
Repeatability and reproducibility of 99mTc-ECD SPECT in dogs have been investigated by 
our research group in previous studies and were found to be highly satisfactory (Waelbers et 
al., 2012). For 99mTc-HMPAO, data in man provided similar results with high reproducibility 
when data were normalized (Jonsson et al., 2000).  
Depending on the indication, the use of one or the other tracer could be more beneficial. In 
specific neurologic or behavioral conditions, it may be more important either to visualize 
specific brain regions (such as the subcortical region which includes the limbic system) or to 
focus on brain perfusion or metabolism. From this perspective, it may be of importance to use 
the most suitable tracer. Future work should therefore explore the specific use of one of the 
tracers in research concerning specific neurological and behavioral conditions both in humans 
and animals. 
F. Conclusion 
The findings from the current study indicate that, while not entirely interchangeable, both 
tracers can be used for visualization of canine cerebral blood flow. Differences in regional 
distribution of both tracers suggest that a selection of either 99mTc-ECD or 99mTc-HMPAO 
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CHAPTER 2: The influence of a single dose of morphine 











































Adapted from: Adriaens A, Peremans K, Waelbers T, Vandermeulen E, Duchateau L, Croubels S, 
Dobbeleir A, Audenaert K, Eersels J, Vermeire S, De Spiegeleer B, Polis I. The effect of morphine on 
canine regional cerebral blood flow measured by 99mTc-ECD SPECT. 2013c (submitted to Res Vet 
Sci).  
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A. Abstract 
Regional cerebral blood flow (rCBF) can be used to assess brain activity patterns 
generated by drugs, in this case morphine, to gain insights in their mechanism of action. The 
aim of this study was to assess the effect of morphine on rCBF in dogs. 
Methods: In a randomized cross-over experimental study, rCBF was estimated by means of 
99mTc-ECD (Ethylcysteinate Dimer) single photon emission computed tomography (SPECT) 
in 8 dogs at baseline, at 30 minutes and at 120 minutes after a single bolus of morphine. The 
perfusion indices (PI) in the frontal, parietal, temporal and occipital cortex and in the 
subcortical and cerebellar region were obtained by semiquantification. 
Results: A significantly decreased PI was found 30 min after morphine compared to baseline 
in the right frontal cortex (P = 0.047). The left parietal cortex and subcortical region showed 
a significantly increased PI 30 min after morphine compared to baseline (P = 0.021 and 0.006 
respectively). No significant differences were noted for the other regions or at other time 
points. 
Conclusions: A single bolus of morphine generated a different rCBF pattern at different time 
points. The cause for this difference should be investigated in future studies. 
  




Morphine, a mu opioid receptor agonist, is a frequently used potent analgesic in dogs 
(Pascoe, 2000a and 2000b). Its pharmacological effect depends on peripheral and supraspinal 
mu opioid receptor (MOR) activation (for review see Yaksh, 1997). Cerebral MORs are 
widely distributed throughout the brain and modulate the transmission and perception of 
painful stimuli (Mansour et al., 1995b).  
Numerous studies have reported on different aspects of the influence of various opioids on 
cerebral hemodynamics, both in animal models and in man (Buchweitz et al., 1984; Hoffman 
et al., 1993; Firestone et al., 1996; Adler et al., 1997; Wagner et al., 2001; Nikolaishvili et al., 
2004; Wagner et al., 2007; Zelaya et al., 2012). However, the effects of opioids on cerebral 
blood flow (CBF) remain unclear due to the variable results (Buchweitz et al., 1984; 
Hoffman et al., 1993; Firestone et al., 1996; Adler et al., 1997; Wagner et al., 2001; 
Nikolaishvili et al., 2004; Wagner et al., 2007; Zelaya et al., 2012). In dogs, only few have 
reported on the hemodynamic effects of morphine on the brain, usually reporting global 
cerebral blood flow changes with varying results (Takeshita et al., 1972; Matsumiya and 
Dohi, 1983; Milde et al., 1989; Rosen et al., 1989; Milde et al., 1990; Werner et al., 1991 
Hoffman et al., 1993). These discrepancies are probably caused by differences in study 
design, imaging technique, species, opioid choice, dose and route of administration. 
It is important to determine whether regional CBF (rCBF) differences occur in order to 
better understand how drugs influence cerebral activity and, therefore, to gain insight on their 
mechanism of action. Particularly in the case of mu opioid analgesics this is interesting since 
their side effects (dependence, tolerance, addiction) are thought to be mainly caused by 
supraspinal mechanisms in which the MOR plays a key role (Whistler, 2012). 
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Single photon emission computed tomography (SPECT) imaging using 99mTc-
Ethylcysteinate Dimer (99mTc-ECD) is a valid method for rCBF evaluation in dogs (Peremans 
et al., 2001). As rCBF is correlated to regional brain activity (Gerrits et al., 1998), it can be 
used to study the effects of different drugs on the canine brain (Waelbers et al., 2011). The 
objective of the present study was to examine the effects of a single dose of morphine on 
rCBF in dogs. Since opiate action is not only dose, but also time dependent (Martin, 1983; 
Fuller and Stein, 1991), SPECT scans were performed at different time intervals after 
morphine administration. 
C. Materials and methods 
1. Animals 
Eight female neutered Beagle dogs (age 4.22 ± 0.35 years, weight 8.58 ± 0.87 kg (mean ± 
standard deviation, SD)) were used for this study. None of the dogs had a history of major 
disease or neurological disorder. The study was approved by the Ghent University Ethical 
Committee (EC 2011-130). All guidelines for animal welfare, imposed by the Ethical 
Committee, were respected. 
2. Study Design 
To investigate the influence of a single rapid bolus of morphine (0.5 mg/kg intravenously, 
Morphine Hydrochloride, Sterop, Belgium) on rCBF, all dogs were scanned 3 times in a 
randomized cross-over study design. The 3 SPECT scans consisted of a baseline scan (no 
morphine, condition ‘Baseline’), a scan where 99mTc-ECD was injected 30 minutes after 
morphine (i.e. T30, condition ‘MOR30’) and a scan where 99mTc-ECD was injected 120 
minutes after morphine (i.e. T120, condition ‘MOR120’). All scans were performed 
following the same anesthetic and image acquisition protocol. Food, but not water, was 
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withheld for 12 hours before each scan. To determine morphine plasma and cerebrospinal 
fluid (CSF) concentrations 2 hours after morphine administration, 5 mL of blood were 
collected from the jugular vein (in a heparinized blood tube) and approximately 2 mL of CSF 
were collected by cisternal puncture from all dogs after the MOR30 scan. Blood was 
centrifuged at 3500 rpm for 5 minutes after which plasma was collected. All samples were 
kept at -20 °C until analysis was performed.  
3. Tracer 
To evaluate rCBF 99mTc-ECD (Neurolite®, Bristol-Myers Squibb Medical Imaging), 
prepared according to the manufacturer’s instructions, was used. 99mTc-ECD passes the 
blood-brain-barrier in its lipophilic form after which it is enzymatically transformed by 
intracellular esterases to a hydrophilic form that remains trapped in the cell. It rapidly reaches 
plateau values in the brain from 5 min onwards thus providing a fixed image of the rCBF 
practically at the moment of 99mTc-ECD injection. Optimal image acquisition is achieved 
between 15 and 40 min after tracer injection (Waelbers et al., 2012). 99mTc-ECD was 
administered intravenously: 747.91 ± 30.22 MBq, 789.16 ± 47.02 MBq and 751.61 ± 40.33 
MBq in the Baseline, MOR30 and MOR120 condition, respectively. 
4. Anesthetic Protocol 
General anesthesia is required for SPECT imaging in animals. To avoid the influence of 
anesthetic drugs on rCBF, the administration of the anesthetics was done after the plateau for 
99mTc-ECD was reached in the canine brain. The dogs were premedicated (intramuscular 
dexmedetomidine 375 µg/m² body surface area, Dexdomitor®, Orion Corporation, Espoo, 
Finland) 15 min after injection of 99mTc-ECD. Anesthesia was induced with propofol (1.74 ± 
0.51 mg/kg intravenously, Propovet®, Abbott Laboratories, Queenborough, United Kingdom) 
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and maintained with isoflurane (Isoflo®, Abbott Laboratories) in oxygen. In order to limit the 
influence of the PaCO2 on cerebral perfusion, dogs were mechanically ventilated 
(intermittent positive pressure ventilation) during anesthesia to preserve PaCO2 within the 
physiologic range, i.e. end tidal CO2 within 35-45 mmHg. 
5. Image Acquisition 
Image acquisition started 10 minutes after induction of anesthesia, i.e. 40 min after 99mTc-
ECD injection. SPECT scans were performed using a triple head gamma camera (Triad 
Trionix, Twinsburg, OH, USA) equipped with ultrahigh resolution parallel hole collimators 
(tomographic resolution, 8 mm full width half maximum). For each acquisition, 120 
projection images were obtained on a 128x128 matrix using a step-and-shoot mode (3° steps, 
10 s per step), with a total scanning time of 20 minutes. During scanning, dogs were 
positioned in ventral recumbency with fixation of the head in a preformed cushion, to prevent 
individual positioning artifacts. Camera and table positioning were recorded to ensure 
optimal intraindividual comparison.  
6. Image Processing 
The images were reconstructed using filtered backprojection and post-filtering with a 
Butterworth filter (cut-off, 1.6 cycles/cm, order 5).  
The emission data were fitted to a template using BRASS software (Brain Registration 
and Automated SPECT Semiquantification, Nuclear Diagnostics, Stockholm, Sweden) that 
allows scaling, rotating, and translating the acquired images in all 3 dimensions. This 
software was developed for humans but the template and regions were created in house for 
the use in dogs (Peremans et al., 2003b). The template provides the necessary anatomical 
references and a predefined region map for a volume-of-interest (VOI) approach. The 
following VOIs were included: right and left frontal, temporal, parietal and occipital cortices, 
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as well as the subcortical and cerebellar region. Perfusion indices (PI) for the different VOIs 
were calculated as the mean count per voxel in each VOI normalized to the mean total brain 
count per total voxel.  
7. Morphine Concentrations 
Plasma and CSF concentrations of morphine were determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method. The quantification was 
based on the use of codeine as an internal standard (IS), which was added to the samples 
prior to analysis. Quality control (QC) and blank samples were analyzed together with each 
batch of incurred samples to check the extraction and LC-MS/MS procedure. All QC, blank 
and calibration curve samples were prepared in pooled drug-free dog plasma and drug-free 
artificial CSF (Tocris Bioscience, Abingdon, United Kingdom). This artificial CSF closely 
matches the electrolyte concentrations of CSF and final ion concentrations (in mM) are: Na 
150; K 3.0; Ca 1.4; Mg 0.8; P 1.0; Cl 155. After addition of 25 µL of the IS working solution 
of 10 µg/mL to 250 µL of the dog plasma and CSF samples, the pH was adjusted by addition 
of 500 µL of a 0.67 M aqueous phosphate buffer of pH 7. After vortex mixing for 15 sec, the 
samples were put on an Oasis® MCX (mixed cation exchange) solid-phase extraction column 
(3 mL, 60 mg; Waters, Milford, MA, USA), previously conditioned with 2 mL of methanol 
and 2 mL of HPLC grade water. Subsequently, the column was washed with 2 mL of HPLC 
water, 1 mL of 0.1 M hydrochloric acid in water and 2 mL of methanol, respectively. 
Morphine and codeine were eluted with 2 mL of dichloromethane/2-propanol/ammonia 
(80/20/2, v/v/v). After evaporation at 50 °C under a gentle stream of nitrogen, the dry residue 
was dissolved in 100 µL of 0.1% formic acid in HPLC water and filtered through a 
polyvinylidene fluoride 0.22 µm filter (Millipore, Billerica, MA, USA). An aliquot of the 
extract (8 µL) was injected onto the LC-MS/MS instrument. The HPLC system consisted of 
Chapter 2: Acute morphine and rCBF in dogs  
 
59 	   	  
an Acquity UPLC® instrument from Waters. The analysis of the extracts was performed on a 
BEH-C18 1.7 µm column (2.1 x 50 mm; Waters), used in combination with a frit. A gradient 
elution with 0.1% formic acid in water (A) and acetonitrile (B) was performed (98% A/2% B, 
0–2 min; 50% A/50% B, 2.1–3 min; 98% A/2% B, 3.1– 8 min). A Quattro Premier® XE MS 
instrument from Waters was used, equipped with an ESI (electrospray ionization) source, 
operated in the positive ion MS/MS mode. The following ion transition was monitored and 
used for quantification: m/z 286 > 165. The limit of detection of the method was calculated to 
be 1.27 ng/mL based on a signal-to-noise ratio of 3/1. The accuracy and precision were 
determined at 10.0 and 50.0 ng/mL in dog plasma (n = 6). The accuracy fell within the range 
of - 20% to +10%, and precision was also within the maximum RSD values as set by the EU 
(Anonymous, 2002). The limit of quantification (LOQ) was defined as the lowest 
concentration in dog plasma and CSF for which the method was validated with an accuracy 
and precision that fall within EU recommended ranges and was set at 5.0 ng/mL. Plasma and 
CSF concentrations below the LOQ were not included in the data analysis. 
8. Statistical Analysis 
To compare PI means between the three conditions, a mixed model was fitted with 
condition (Baseline, MOR30 and MOR120) as fixed effect and dog as random effect. 
Correlation between morphine plasma and CSF concentration was investigated by means of 
Kendall τ  correlation coefficients. 
Significance was set at P < 0.05. All data are presented as mean ± SD. 
D. Results 
Table 1 depicts PIs for all VOIs in the different conditions. Mean PIs of the right frontal 
cortex, left parietal cortex and the subcortical region differed significantly between 
conditions. Pairwise comparison revealed that morphine administration only altered the rCBF 
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in those regions compared to the baseline condition at T30 (P = 0.047, 0.021 and 0.006 
respectively). No significant differences were found when comparing Baseline to MOR120 
or MOR30 to MOR120. 
Table 1. Perfusion indices for the different conditions (Baseline, MOR30 and MOR120) in all brain regions in 8 
dogs (mean ± SD). 
Brain region Baseline MOR30 MOR120  P 
Left frontal 1.12 ± 0.05 1.12 ± 0.06 1.12 ± 0.04 0.89 
Right frontal 1.12 ± 0.02 1.06 ± 0.07 1.11 ± 0.04 0.04* 
Left temporal 0.86 ± 0.02 0.90 ± 0.07 0.89 ± 0.05 0.23 
Right temporal 0.85 ± 0.05 0.85 ± 0.04 0.90 ± 0.05 0.09 
Left parietal 1.12 ± 0.07 1.21 ± 0.06 1.19 ± 0.07 0.02* 
Right parietal 1.11 ± 0.04 1.15 ± 0.10 1.20 ± 0.09 0.08 
Left occipital 1.08 ± 0.07 1.09 ± 0.13 1.00 ± 0.07 0.12 
Right  occipital 1.07 ± 0.05 1.07 ± 0.14 1.02 ± 0.08 0.36 
Subcortical 1.24 ± 0.03 1.29 ± 0.04 1.26 ± 0.05 0.01* 
Cerebellum 1.05 ± 0.02 1.04 ± 0.06 1.00 ± 0.06 0.14 
Data compared with mixed model. *Pairwise comparisons revealed a significant difference between Baseline 
and MOR30 in RF, LP and SC (P = 0.047, 0.021 and 0.006 respectively). 
Two CSF samples had morphine concentrations below the LOQ and were not used for further 
analysis. Morphine plasma and CSF concentrations 2 hours after morphine administration 
were 13.50 ± 3.75 ng/mL and 17.52 ± 1.32 ng/mL, respectively (individual concentrations 
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are presented in Table 2). There was no significant correlation between morphine 
concentrations in plasma and CSF (Kendall τ correlation coefficient 0.43 and P = 0.14). 
Table 2. Morphine concentrations (ng/mL) in plasma and CSF in 8 dogs 120 minutes after intravenous 
morphine administration at a dose of 0.5 mg/kg. 
Dog Plasma CSF 
1 16.9 17.6 
2 12.6 19.1 
3 18.0 18.5 
4 10.1 15.7 
5 7.2 < LOQ 
6 15.3 18.0 
7 16.3 < LOQ 
8 11.6 16.2 
LOQ: Limit of quantification of 5 ng/mL. 
E. Discussion 
The current study investigated changes in rCBF after morphine administration in dogs at 
two different time points. In non-painful dogs, a single dose of morphine induced rCBF 
changes in the frontoparietal cortex after 30 minutes compared to baseline values. We found 
a decreased blood flow in the frontal cortex and an increased blood flow in the parietal 
cortex. These brain regions are known to be involved in the complex - and not yet completely 
understood - mechanism of pain perception, i.e. the cognitive and affective-motivational 
aspects of nociception (for review see Ohara et al., 2005). Additionally, an increased CBF 
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was found in the subcortical region which includes structures important for pain modulation 
such as the thalamus and the periaqueductal gray (for review see Willis and Westlund, 1997). 
Alterations in rCBF reflect alterations in brain activity, i.e. increased brain activity requires 
increased blood supply and vice versa (Gerrits et al., 1998). It is therefore not surprising to 
find rCBF changes in regions involved in the modulation and perception of pain after the 
administration of a potent analgesic such as morphine. Furthermore, the present results are in 
line with a study in humans on the effects of opioids and provoked pain on rCBF (Wagner et 
al., 2007). In that study it was found that regions involved in the modulation of pain were 
activated, whereas regions that are involved in the perception of pain showed a decreased 
rCBF after opioid administration (Wagner et al., 2007).  In dogs, the effects of opioids on 
global CBF have been investigated and decreased as well as increased global CBF have been 
reported (Matsumiya and Dohi, 1983; Milde et al., 1990; Werner et al., 1991). However, to 
our knowledge, the effect of opioids on regional CBF has not yet been studied in dogs.  
Remarkably, we only found a significant difference in rCBF between MOR30 and 
Baseline and not between MOR120 and Baseline. In a study in dogs using remifentanil, 
decreased blood flow and decreased EEG activity were described in the cortex, hippocampus 
and caudate nucleus (Hoffman et al., 1993). These changes recovered to baseline levels after 
30 minutes (Hoffman et al., 1993). Since morphine is a longer acting opioid, it is possible 
that a comparable return to baseline brain activity occurs at a later time point. 
The morphine plasma concentrations at T120 were 13.50 ± 3.75 ng/mL, these are 
consistent with concentrations needed to achieve 50% of maximal effect obtained in a 
pharmacodynamic study in dogs, i.e. 13,92 ± 2,39 ng/mL (KuKanich et al., 2005). In that 
study it was also reported that a significant analgesic level was present for only 2.8 ± 0.6 
hours (KuKanich et al., 2005). In a clinical setting on the other hand, morphine is usually 
administered every 4 hours to maintain proper analgesia (Lamont and Matthews, 2007). In a 
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study in dogs on the pharmacokinetics of morphine, CSF concentrations at T120 were higher 
than plasma concentrations, as is the case in our study for most dogs and the range of CSF 
concentrations at T120 is also comparable to our results (Table 2) (Hug et al., 1981). It was 
additionally described that morphine appears to accumulate in CSF over time after systemic 
administration, since it has a longer halftime in CSF (121 ± 6 min) compared to plasma (75 ± 
5 min) and the CSF-to-plasma concentration gradient increases progressively (Hug et al., 
1981).  
Taken together with our results, at T120 after morphine administration, we know that 
plasma and CSF concentrations are clincally relevant, however, no changes in blood flow – 
and thus brain activity – are detectable at that time point. This could possibly suggest that 
morphine exerts its effect at a different level than the brain at this time point, i.e. a peripheral 
action (spinal or at the periphery) rather than supraspinal action. This possibly insinuates a 
time-dependent localization of the analgesic effect of morphine, which would be interesting 
for further investigation in future studies.  
As for the effects of opioids on cerebral hemodynamics in dogs, it is rather unlikely that 
changes in systemic cardiovascular parameters would cause regional alterations in CBF. 
Morphine at clinically relevant doses has limited influence on systemic cardiovascular 
parameters such as heart rate and blood pressure (Guedes et al., 2007; Maiante et al., 2009). 
Additionally, if proper ventilation is assured (opioids can cause respiratory depression), the 
effects of opioids on cerebral hemodynamics are limited (Armitage-Chan et al., 2007).  
Several explanations for the alterations in rCBF caused by opioids have been suggested. 
The observed rCBF changes are most likely the result of changes in neuronal activity since 
MOR activation in itself causes increased energy demand, thus increasing blood flow. An 
effect of opioids on cerebral vasculature has also been proposed, either direct or indirect. 
Opioid receptors are found on cerebral vasculature (Peroutka et al., 1980) and opioids have 
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been found to be vasodilators (Wahl, 1985). However, this would imply that changes in rCBF 
are only related to MOR density, which is not always the case due to the widespread 
distribution of cerebral MORs (Trusk and Stein, 1987; Mansour et al., 1995b; Firestone et al., 
1996; Khalili-Mahani et al., 2011) and the widespread influence of opioids on different 
neurotransmitter systems, including vasoactive systems such as nitric oxide, prostanoids or 
vasopressin (Armstead et al., 1990; Devine and Armstead, 1995; Armstead, 1996). 
F. Conclusion 
The present study found an altered rCBF pattern 30 minutes after morphine compared to 
baseline values. Pain is a complex phenomenon and unraveling the mode of action of 
analgesics such as opioids appears to be equally challenging, involving various cerebral 
regions. On top of this, the possibly time-dependent rCBF pattern found after morphine raises 
new questions on the correct interpretation of data and the comparison with other results. 
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A. Abstract 
The aim of the present study was to assess the influence of a prolonged morphine 
administration on the regional cerebral blood flow (rCBF) in dogs using functional brain 
imaging. 
Methods: The rCBF was evaluated with 99mtechnecium labeled hexamethylpropylene amine 
oxime (99mTc-HMPAO) single photon emission computed tomography (SPECT) in 8 dogs. 
All dogs were scanned at baseline and after 10 days of oral treatment with sustained release 
morphine sulphate in a randomized cross-over study. Perfusion was determined by 
normalizing regional perfusion (left and right frontal, parietal, temporal and occipital cortices 
and the subcortical and cerebellar regions) to total brain perfusion. Additionally, plasma and 
cerebrospinal fluid (CSF) morphine concentrations were determined by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). 
Results: No significant changes in rCBF pattern could be detected. Plasma concentrations 
were consistently higher than CSF concentrations (ratio 5.74), but no correlation was found 
between both.  
Conclusions: Despite clinically relevant plasma concentrations, the prolonged administration 
of morphine did not alter rCBF patterns in the canine brain. 
  




Morphine, a potent and frequently used analgesic in dogs and humans, is most commonly 
applied in cases of acute pain like perioperative pain management. Its use in chronic pain 
management in humans and animals is hindered due to the long-term side effects that can 
occur, such as tolerance, addiction and dependence. Functional imaging studies in man have 
mainly investigated cerebral blood flow alterations in subjects that had a history of substance 
abuse, including states of withdrawal, abstinence, craving and opioid maintenance therapy 
(van Dyck et al., 1994; Krystal et al., 1995; Danos et al., 1998; Rose et al., 1996; Schlaepfer 
et al., 1998; Pezawas et al., 2002; Guyer et al., 2007; Kosel et al., 2008; Suh et al., 2009). 
However, due to the great variation in study design, results are not consistent. Since animals 
are less likely to develop dependence and addiction, the most important side effect of long-
term use of opioids in veterinary medicine, is the loss of therapeutic effect due to the 
development of tolerance. 
Regional cerebral blood flow (rCBF) is known to be a measure for regional brain activity 
(Sokoloff et al., 1977; Gerrits et al., 1998). Therefore, by examining the rCBF changes 
produced by a drug with a supraspinal action, such as morphine, the rCBF pattern can be 
used to gain insights into its mode of action and to compare it with patterns generated by 
other drugs. To evaluate the rCBF in vivo in a non-invasive manner, single photon emission 
computed tomography (SPECT) with neuroperfusion tracers such as 99mTc-ECD 
(ethylcysteinate dimer) and 99mTc-HMPAO (hexamethylpropylene amine oxime) is a 
frequently used technique (Kapucu et al., 2009). The use of animal brain imaging studies 
provides advantages in drug research including the possibility to perform longitudinal brain 
imaging studies (less radioprotection issues, shorter life spans), ex vivo analysis of the brain 
after the imaging study, and assessment of new drugs prior to approval for human use 
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(review: Thompson and Bushnell, 2012). In this regard, both 99mTc-labelled tracers have been 
successfully used to investigate rCBF in dogs (Peremans et al., 2001 and 2003b; Martlé et al., 
2009; Waelbers et al., 2011 and 2012; Adriaens et al., 2013a).  
A recent study from our group investigated the effect of a single bolus of morphine on 
rCBF in dogs and found a time-dependent change in the rCBF pattern (Adriaens et al., 2013c 
(submitted)). Therefore, the present study aimed at determining whether a prolonged 
exposure to morphine at clinically relevant doses would induce similar or different changes in 
rCBF. 
C. Materials and Methods 
1. Animals 
The study was approved by the Ghent University Ethical Committee (EC 2011-130). All 
guidelines for animal welfare, imposed by the Ethical Committee, were respected. Eight 
female neutered Beagle dogs (age 5.20 ± 0.34 years, weight 8.53 ± 0.87 kg (mean ± standard 
deviation, SD)) were used for this study. None of the dogs had a history of major disease or 
neurological disorder. 
2. Study Design 
To evaluate the influence of a 10-day morphine treatment on rCBF, all dogs underwent 2 
SPECT scans, i.e. Baseline and Morphine condition, in a randomized cross-over study (wash 
out period of 3 weeks). The Morphine condition scan was performed after a 10 days 
administration period of 20 mg oral sustained release morphine sulphate dosed twice daily 
(MS Contin®, Mundipharma, Mechelen, Belgium), which corresponds to 2.37 ± 0.25 mg 
morphine/kg twice daily. 
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The dogs were monitored closely (respiratory rate, heart rate and quality, degree of 
sedation, nausea and emesis) for 3 hours after morphine administration and side effects were 
noted if observed. 
Food, but not water, was withheld for 12 hours before each scan. To check whether the 
given morphine dosage was clinically relevant, morphine plasma concentrations were 
determined. For this, 5 mL of heparinized blood were collected from the jugular vein at 3 
hours after the last morphine administration and before the Morphine scan. Blood was 
centrifuged at 3500 rpm for 5 min and plasma was collected. At the end of the Morphine 
scan, a cerebrospinal fluid (CSF) sample (2mL, collected by cisternal tap) was taken. All 
samples were kept at -20 °C until analyzed 
3. Tracer 
To evaluate rCBF 99mTc-HMPAO (Ceretec®, GE Healthcare) was used and prepared 
according to the manufacturer’s instructions. The 99mTc-HMPAO was administered 
intravenously: 361.58 ± 13.11 MBq and 339.75 ± 21.91 MBq in the Baseline and Morphine 
condition, respectively. 99mTc-HMPAO readily passes the blood-brain-barrier in its lipophilic 
form after which it is transformed to a hydrophilic form depending on the glutathione content 
and redox equilibrium in the cell (Jacquier-Sarlin et al., 1996a). This hydrophilic form then 
remains trapped in the cell.  
4. Anesthetic Protocol 
General anesthesia is required for SPECT imaging in animals. The dogs were 
premedicated with an intramuscular injection of dexmedetomidine at 375 µg/m² body surface 
area, Dexdomitor®, Orion Corporation, Espoo, Finland) once the plateau was reached for the 
rCBF tracer, i.e. 10 min after injection of 99mTc-HMPAO (Susskind et al., 1996). Anesthesia 
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was induced intravenously with propofol (1.69 ± 0.75 mg/kg intravenously, Propovet®, 
Abbott Laboratories, Queenborough, United Kingdom) and maintained with isoflurane 
(Isoflo®, Abbott Laboratories) in oxygen. In order to limit the influence of the PaCO2 on 
cerebral perfusion, the dogs were mechanically ventilated (by intermittent positive pressure 
ventilation) during anesthesia to preserve PaCO2 within the physiologic range, i.e. end tidal 
CO2 within 35-45 mmHg. 
5. Image Acquisition 
Image acquisition started 10 minutes after induction of anesthesia, i.e. 35 min after 99mTc-
HMPAO injection. SPECT scans were performed using a triple head gamma camera (Triad 
Trionix, Twinsburg, OH, USA) equipped with ultrahigh resolution parallel hole collimators 
(tomographic resolution, 8 mm full width half maximum). For each acquisition, 120 
projection images were obtained on a 128x128 matrix using a step-and-shoot mode (3° steps, 
15 s per step), with a total scanning time of 30 minutes. During scanning, the dogs were 
positioned in ventral recumbency with the head fixated in a preformed cushion, to prevent 
individual positioning artifacts. Camera and table positioning were recorded to ensure 
optimal intraindividual comparison. 
6. Image Processing 
The images were reconstructed using filtered backprojection and post-filtered using a 
Butterworth filter (cut-off 1.6 cycles/cm, order 5).  
The emission data were fitted to a template using BRASS software (Brain Registration 
and Automated SPECT Semiquantification, Nuclear Diagnostics, Stockholm, Sweden) that 
allows scaling, rotating, and translating of the acquired images in all 3 dimensions. This 
software was developed for humans but the template and regions were created in house for 
the use in dogs (Peremans et al., 2003b). The template provides the necessary anatomical 
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references and a predefined region map for a volume-of-interest (VOI) approach. The 
following VOIs were included: right and left frontal, temporal, parietal and occipital cortices, 
as well as the subcortical and cerebellar region. Perfusion indices (PI) for the different VOIs 
for each dog were calculated as the count per voxel of the VOI normalized to the count per 
voxel of the whole brain. 
7. Morphine Concentrations 
Plasma and CSF concentrations of morphine were determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method. The quantification was 
based on the use of codeine as an internal standard (IS), which was added to the samples 
prior to analysis. Quality control (QC) and blank samples were analyzed together with each 
batch of incurred samples to check the extraction and LC-MS/MS procedure. All QC, blank 
and calibration curve samples were prepared in pooled drug-free dog plasma and drug-free 
artificial CSF (Tocris Bioscience, Abingdon, United Kingdom). This artificial CSF closely 
matches the electrolyte concentrations of CSF and final ion concentrations (in mM) are: Na 
150; K 3.0; Ca 1.4; Mg 0.8; P 1.0; Cl 155. After addition of 25 µL of the IS working solution 
of 10 µg/mL to 250 µL of the dog plasma and CSF samples, the pH was adjusted by addition 
of 500 µL of a 0.67 M aqueous phosphate buffer. After vortex mixing for 15 sec, the samples 
were put on an Oasis® MCX (mixed cation exchange) solid-phase extraction column (3 mL, 
60 mg; Waters, Milford, MA, USA), previously conditioned with 2 mL of methanol and 2 
mL of HPLC grade water. Subsequently, the column was washed with 2 mL of HPLC water, 
1 mL of 0.1 M hydrochloric acid in water and 2 mL of methanol, respectively. Morphine and 
codeine were eluted with 2 mL of dichloromethane/2-propanol/ammonia (80/20/2, v/v/v). 
After evaporation at 50 °C under a gentle stream of nitrogen, the dry residue was dissolved in 
100 µL of 0.1% formic acid in HPLC water and filtered through a polyvinylidene fluoride 
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0.22 µm filter (Millipore, Billerica, MA, USA). An aliquot of the extract (8 µL) was injected 
onto the LC-MS/MS instrument. The HPLC system consisted of an Acquity UPLC® 
instrument from Waters. The analysis of the extracts was performed on a BEH-C18 1.7 µm 
column (2.1 x 50 mm; Waters), used in combination with a frit. A gradient elution with 0.1% 
formic acid in water (A) and acetonitrile (B) was performed (98% A/2% B, 0–2 min; 50% 
A/50% B, 2.1–3 min; 98% A/2% B, 3.1– 8 min). A Quattro Premier® XE MS instrument 
from Waters was used, equipped with an ESI (electrospray ionization) source, operated in the 
positive ion MS/MS mode. The following ion transition was monitored and used for 
quantification: m/z 286 > 165. The limit of detection of the method was calculated to be 1.27 
ng/mL based on a signal-to-noise ratio of 3/1. The accuracy and precision were determined at 
10.0 and 50.0 ng/mL in dog plasma (n = 6). The accuracy fell within the range of - 20% to 
+10%, and precision was also within the maximum RSD values as set by the EU 
(Anonymous, 2002). The limit of quantification (LOQ) was defined as the lowest 
concentration in dog plasma and CSF for which the method was validated with an accuracy 
and precision that fall within EU recommended ranges and was set at 5.0 ng/mL. 
8. Statistical Analysis 
The means of the obtained PIs from Baseline and Morphine were compared using a mixed 
model with treatment as fixed effect and dogs as random effects. Significance was set at P < 
0.05. Correction for multiple comparisons was applied by means of Bonferroni correction. 
Correlation between morphine plasma and CSF concentrations was investigated by 
calculating the Kendall’s τ correlation coefficient. Plasma to CSF ratio was calculated, as 
well as the mean of the ratios. 




The comparison of the mean PIs of the Baseline and Morphine conditions did not reveal 
statistically significant differences (Table 1). The observed differences for any of the regions 
were small.  
 
Table 1. Perfusion indices (PI) for the Baseline and Morphine conditions measured with 99mTc-HMPAO in 8 
dogs (mean ± SD). 
VOI Baseline Morphine P 
Left frontal 1.13 ± 0.03 1.13 ± 0.06 0.67 
Right frontal 1.14 ± 0.03 1.12 ± 0.04 0.43 
Left temporal 0.88 ± 0.03 0.89 ± 0.04 0.50 
Right temporal 0.87 ± 0.05 0.88 ± 0.06 0.89 
Left parietal 1.12 ± 0.05 1.13 ± 0.05 0.53 
Right parietal 1.10 ± 0.04 1.11 ± 0.05 0.58 
Left occipital 1.11 ± 0.08 1.12 ± 0.08 0.69 
Right  occipital 1.11 ± 0.06 1.10 ± 0.08 0.79 
Subcortical 1.15 ± 0.04 1.19 ± 0.05 0.092 
Cerebellum 1.12 ± 0.08 1.13 ± 0.05 0.93 
Individual morphine plasma and CSF concentrations can be found in Table 2. Mean 
plasma concentrations were 47.60 ± 9.74 ng/mL and mean CSF concentrations were 9.53 ± 
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3.12 ng/mL. No correlation was found between the morphine plasma and CSF concentrations 
(Kendall τ correlation coefficient 0.43, P = 0.14). Additionally, the plasma/CSF ratios for 
each dog are represented in Table 2. The mean plasma/CSF ratio was 5.74. 
 
 
Table 2. Individual morphine plasma and CSF concentrations (ng/mL) on the last day of morphine treatment 
(20 mg oral sustained release morphine sulphate twice daily for 10 days) in 8 dogs. 
Dog Plasma CSF Plasma/CSF Ratio 
1 59.71 13.3 4.50 
2 47.33 13.1 3.62 
3 36.08 < LOQ (3.95) - 
4 51.97 8.5 6.14 
5 59.31 6.8 8.75 
6 35.79 5.9 6.07 
7 51.56 9.6 5.35 
8 39.05 < LOQ (4.36) - 
LOQ: Limit of quantification of 5 ng/mL 
E. Discussion 
A prolonged opioid treatment consisting of 10 days of morphine administration resulted in 
clinically relevant morphine concentration levels in plasma and CSF, but did not alter the 
rCBF pattern in non-painful dogs. 
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The dogs were given a 10-day morphine treatment during which the aim was not to induce 
tolerance, dependence or addiction. Rather, the duration of the treatment was chosen to create 
a longer period of treatment than what is usually administered during regular post-operative 
care. That way, the effects of a prolonged administration of morphine could be explored. 
Morphine can be used to treat chronic pain in small animals, but it is hindered by side effects 
and legal issues, therefore, the preference is usually given to non-steroidal anti-inflammatory 
drugs (Fox, 2010). In the present study, the 10-day morphine treatment was well tolerated by 
all dogs, supporting the possible use of morphine for longer periods. Additionally, a previous 
study from our group found that a similar morphine treatment induced changes in the 5-
HT2A receptor system, which can be beneficial for 5-HT2A receptor-related diseases where 
prolonged treatment is often required (Adriaens et al., 2012b). 
No difference in rCBF pattern could be detected in the present study. However, in the 
subcortical region, a small increase, though not significant, could be found in the morphine 
treated dogs. As mentioned, it is difficult to compare the present results to those in literature 
since most studies were conducted in man and studies involving prolonged administration of 
opioids generally focus on patients suffering from addiction, during abstinence, withdrawal 
craving or opioid maintenance therapy (Van Dyck et al., 1994; Krystal et al., 1995; Rose et 
al., 1996; Danos et al., 1998; Schlaepfer et al., 1998; Pezawas et al., 2002; Guyer et al., 2007; 
Kosel et al., 2008; Suh et al., 2009). Furthermore, due to the great variation in study design, it 
is often difficult to compare different, even contradictory, results. However, changes in rCBF 
– whether these were increases or decreases – were most consistently found in structures that 
are part of the limbic system (Krystal et al., 1995; Rose et al., 1996; Schlaepfer et al., 1998; 
Pezawas et al., 2002; Guyer et al., 2007; Suh et al., 2009). In this light, the present finding, 
although not statistically significant, of an increased rCBF in the subcortical region, which 
includes limbic structures such as the thalamus, is not entirely surprising. 
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The plasma and CSF morphine concentrations found are reported to be adequate to 
provide profound analgesia in dogs (Hug, 1981; KuKanich et al., 2005; Dohoo and Tasker, 
1997). The variation in morphine plasma concentrations has also been described in other 
studies on oral morphine administration in dogs (Dohoo and Tasker, 1997) and no significant 
correlation between plasma and CSF concentrations was found. Additionally, morphine 
concentrations in plasma were consistently higher compared to those in CSF (plasma/CSF 
ratio 5.74).  
In a previous study investigating the influence of a single bolus of morphine on rCFB in 
dogs, a possibly time-dependent effect of morphine was suggested. The alterations in rCBF in 
the cortical and subcortical regions found 30 min after morphine, returned to baseline values 
2 hours after morphine administration. Even though the results of the latter study cannot be 
directly compared to those of the present study due to the use of a different radioligand 
(Adriaens et al., 2013a), it is striking that in both cases, despite the clinically relevant plasma 
concentrations of morphine, no significant alterations in rCBF were found. Interestingly, the 
same 10-day morphine treatment did produce changes in the cerebral serotonergic system in 
dogs, supporting that there is a supraspinal action, even though this is not reflected by blood 
flow changes (Adriaens et al., 2012b). This, however, remains to be further elucidated and 
should be of interest for future investigations on the complex mechanisms of opioid receptor 
internalization and desensitization. Additionally, the significance of the present studies and 
the relevance to pathophysiology of chronic opioid (ab)use also need further investigation.  




The prolonged administration of oral morphine in dogs resulted in clinically relevant 
plasma concentrations and did not alter the rCBF pattern measured by 99mTc-HMPAO 
SPECT. The use of oral morphine over a prolonged period was well tolerated and supports its 
use in perioperative pain management. The lack of significant rCBF alterations is in line with 
a previous report on the effect of morphine on rCBF in dogs. 
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CHAPTER 4:  The influence of a single dose of morphine 
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A. Abstract 
The opioid and serotonergic systems are closely involved in pain processing and mood 
disorders. The aim of this study was to assess the influence of systemic morphine on cerebral 
5-HT2A receptor binding in dogs using single photon emission computed tomography 
(SPECT) with the 5-HT2A radioligand 123I-5I-R91150.  
Methods: The 5-HT2A receptor binding was estimated with (M) and without (C) morphine 
pre-treatment in eight dogs. The 5-HT2A receptor binding indices (BIs) in the frontal, 
parietal, temporal and occipital cortex and in the subcortical region were obtained by 
semiquantification. 
Results: A significantly decreased 5-HT2A receptor BI was found in M for the right (M = 
1.41 ± 0.06, C = 1.53 ± 0.10) and left (M = 1.44 ± 0.08, C = 1.55 ± 0.11) frontal cortices with 
P = 0.012 and P = 0.040, respectively. No significant differences were noted for the other 
regions. 
Conclusions: Morphine decreased the frontocortical 5-HT2A receptor availability, 
confirming an interaction between the 5-HTergic and the opioid system. Whether this is 
caused by decreased receptor density due to direct internalization or the result of indirect 
actions, such as increased endogenous serotonin release, remains to be elucidated. 	   	  




It is well documented that there is a close interaction between the brain opioid and 
serotonin (5-hydroxytryptamine, 5-HT) neurotransmitter systems (Bardon and Ruckebusch, 
1984; Tao and Auerbach, 1994; Zhao et al., 2007). Activation of the mu opioid receptor 
(MOR) system leads to 5-HTergic changes, including increased release of synaptic 5-HT. 
This was shown in several brain regions and in the spinal cord in various in vivo 
microdialysis studies (Bardon and Ruckebusch, 1984; Tao and Auerbach, 1994). 
Furthermore, pharmacological and behavioral studies pointed out that the 5-HTergic system 
is implicated in spinal pain transmission, modulation and control and particularly in the 
mediation of opioid analgesia (Bardin et al., 2000; Zhao et al., 2007). Morphine-induced 
analgesia is thought to rely in part on the indirect activation of descending inhibitory 5-
HTergic pathways (Zhao et al., 2007). Consequently, antidepressants that inhibit 5-HT 
reuptake, such as fluvoxamine and fluoxetine, are also known to have analgesic properties, 
especially in chronic pain states (Honda et al., 2006; Verdu et al., 2008).  
Beside their role in pain modulation (Kayser et al., 2007; Van Steenwinckel et al., 2008; 
Kupers et al., 2009), 5-HT2A receptors gained interest over the last decades due to their 
involvement in several neurological disorders in humans, including anxiety (Nic 
Dhonnchadha et al., 2003), depression (Mintun et al., 2004), schizophrenia (Rasmussen et al., 
2010) and obsessive-compulsive disorder (Rojas-Corrales et al., 2007). More specifically, 
atypical antipsychotic drugs acting as 5-HT2A antagonists and inverse agonists were seen to 
be effective in reducing the symptoms of these diseases (Nic Dhonnchadha et al., 2003; 
Marek et al., 2003). Since the opioid system has been shown to be involved in several of 
these mood disorders as well (Rojas-Corrales et al., 2002), the interaction between MORs 
and 5-HT2A receptors at an emotional and/or cognitive level gained interest, partly with 
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regard to common opioid side effects such as tolerance and addiction that are thought to have 
a serotonergic component as well. Consequently, several in vitro and agonist-antagonist 
behavioral studies were conducted in rodents, giving further evidence for this opioid-
serotonin interaction (Marek and Aghajanian, 1998b; Marek, 2003; Rojas-Corrales et al., 
2007; López-Giménez et al., 2008). 
Functional brain imaging is a valuable tool for the investigation of neurotransmitter 
systems in vivo and is thus commonly used in research involving both neurological disorders 
and pain. The visualization of the brain 5-HT2A receptor system in dogs with SPECT and the 
radioligand 123I-5-I-R-91150 was proven to be efficacious in several studies. Studies 
regarding the role of the 5-HT2A receptor system in canine anxiety, aggression and aging 
supported the application of a dog model as a suitable model for human disease (Peremans et 
al., 2002b; Peremans et al., 2003b; Vermeire et al., 2009). 
The aim of the present study was to assess the influence of morphine on central 5-HT2A 
receptors in dogs. More specifically, the possible change in 5-HT2A receptor availability 
after an acute dose of morphine was investigated by means of functional brain imaging. 
C. Materials and Methods 
1. Animals 
This study was approved by the Ghent University Ethical Committee (EC 2008-143). All 
guidelines for animal welfare, imposed by the Ethical Committee, were respected. To 
minimize gender, breed and age influence, eight female neutered Beagle dogs of 
approximately five years old were used for this study. The dogs weighted 13.04 ± 1.06 kg 
(mean ± standard deviation, SD). None of the dogs had a history of previous major disease or 
neurological disorder. 
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2. Study Design 
To assess the possible influence of morphine on the binding index (BI) of the 5-HT2A 
receptor radioligand, BIs obtained by SPECT after morphine pre-treatment (M group) were 
compared to the BIs obtained without morphine pre-treatment (control or C group). Each dog 
was scanned twice (non-randomized) with a washout period between the C and M scan of at 
least two months. Images were acquired 90 minutes post radioligand injection, based on 
previous results concerning the optimal scanning time (Peremans et al., 2002a). The injected 
tracer activity was 14.73 ± 3.71 MBq/kg bodyweight (BW) for the C group and 15.42 ± 1.21 
MBq/kg BW for the M group (mean ± SD). In the M group, morphine pre-treatment (0.5 
mg/kg BW, Morphine HCl, Sterop, Brussels, Belgium) was administered intravenously, 
injected manually over 1 minute, 30 minutes prior to radioligand injection. The used 
morphine dose is based on a clinically relevant dosage in dogs (Lamont and Matthews, 
2007). 
3. Tracer 
123I-5-I-R91150 is synthesized by electrophilic substitution on the 5-position of the 
methoxybenzamide group of R91150, followed by purification with high-performance liquid 
chromatography and was obtained from the Nuclear Medicine and PET research department 
of the VU University Medical Centre (Amsterdam, The Netherlands). The product had a 
radiochemical purity of more than 99 % and was sterile and pyrogen free. A specific activity 
of 370 GBq/µmol was obtained. The radioligand is a 5-HT2A antagonist with high affinity 
(Kd = 0.11 nM) and selectivity for the 5-HT2A receptor. The selectivity of the ligand for 5-
HT2A receptors with regard to other neurotransmitter receptors such as other 5-HT receptors, 
including 5-HT2C and 5-HT1A, dopamine receptors, adrenergic receptors and histamine 
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receptors is at least a factor 50. The tracer is displaceable with ketanserin, a 5-HT2 antagonist 
(Catafau et al., 2006) and has been shown to be 5-HT2A receptor-specific in dogs (Mertens et 
al., 1994; Peremans et al., 2002a). 
4. Anesthetic Protocol 
All dogs were sedated prior to general anesthesia with intramuscular dexmedetomidine 
375 µg/m2 body surface area. (Dexdomitor®, Orion Corporation, Espoo, Finland). Anesthesia 
was induced with intravenous propofol (Propovet®, Abbott Laboratories, Queenborough, 
United Kingdom), i.e. 2.22 ± 0.40 mg/kg BW for the C group and 1.55 ± 0.31 mg/kg BW for 
the M group (mean ± SD). Anesthesia was maintained, after endotracheal intubation, with 
isoflurane (Isoflo®, Abbott Laboratories, Queenborough, United Kingdom) (1.4% end tidal 
concentration) in oxygen using a rebreathing system. Acquisition started 10 minutes after 
induction of anesthesia. The dogs were mechanically ventilated by intermittent positive 
pressure ventilation to maintain eucapnia, i.e. end tidal CO2 within 35-45 mmHg, in order to 
limit the influence of PaCO2 on cerebral perfusion.   
5. Image Acquisition 
The dogs were positioned in ventral recumbency with fixation of the head in a preformed 
cushion, to prevent individual positioning artefacts. SPECT was performed with a triple head 
gamma camera (Triad Trionix, Twinsburg, OH, USA) equipped with ultrahigh resolution 
parallel hole collimators (Tomographic resolution, 8 mm full width half maximum). Images 
were acquired 90 minutes post injection of the radioligand. Total acquisition time was 30 
minutes. For each acquisition, 90 projection images were obtained on a 128x128 matrix using 
a step-and-shoot mode (20 s/step, 4° steps). Camera and table positioning were recorded to 
ensure optimal ‘intraindividual’ comparison. 
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6. Image Processing 
The radioligand data were reconstructed using the HERMES HybridRecon program 
(HERMES Medical Solutions, Stockholm, Sweden). The reconstruction is based on an 
ordered subset expectation maximization-based reconstruction algorithm with attenuation 
(using a CT transmission scan), collimator response and Monte Carlo-based scatter 
correction.  The details of the reconstruction algorithm can be found in Sohlberg et al., 2008. 
The 123I-5-I-R91150 emission data were fitted to a template based on previously obtained 
cerebral perfusion data using multimodality software (version 5.0; Nuclear Diagnostic AB). 
This software displays images in a dual-window setting and allows for manual co-registration 
by providing tools for scaling, rotating, and translating images in all 3 dimensions. The 
perfusion data provide the necessary anatomical references using the volume-of-interest 
(VOI) approach. Following ROIs were included: right and left frontal, temporal, parietal and 
occipital cortices, as well as the subcortical and cerebellar region. The cerebellum, a region 
with low densities of 5-HT2A receptors, is used as a reference region for non-specifically 
bound and free radioligand. Consequently, the measured radioactivity in the cortical regions 
represents the total activity, i.e. specific and non-specific bound and free radioligand. The BI 
was operationally calculated as ([counts per pixel in VOI] - [counts per pixel in cerebellum]) 
/ (counts per pixel in cerebellum). This BI is proportional to the in vivo density of available 
receptors under pseudoequilibrium conditions (Pazos et al., 1987). 
7. Statistical Analysis 
The injected radioligand dose per kg BW and the injected propofol dose were compared 
between the two treatment groups using the t-test. Changes in 5-HT2A binding with and 
without morphine pre-treatment were compared using the mixed model with ‘treatment’ and 
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‘ROI’ as categorical fixed effects and ‘dog’ as random effect. Left-right differences within 
groups were compared using a paired t-test. Data are presented as mean ± SD. Level of 
significance was set at P < 0.05.  
D. Results 
No severe adverse reactions were seen after the morphine administration. All dogs were 
variably sedated. Some dogs showed mild nausea (n = 4) and panting (n = 4) and one dog had 
a short period of mild excitation. None of the dogs vomited.  
No significant differences were found between the two treatment groups for the injected 
radioligand dose per kg BW. A significant difference was found for the propofol dose per kg 
BW between groups, namely dogs in the M group required a lower propofol dose for 
induction (P = 0.0013). 
Table 1 represents the 5-HT2A BIs in the different VOIs for both groups. A significantly 
lower BI in the left (P = 0.040) and right (P = 0.012) frontal cortex was found in the dogs 
pre-treated with morphine compared to the control group (Table 1). The decreased 5-HT2A 
receptor availability in the frontal cortex after morphine treatment can be visually appreciated 
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Table 1 5-HT2A binding indices with (M) and without (C) morphine pre-treatment (0.5 mg/kg IV) in 8 dogs 
(mean ± SD). 
VOI C M P 
Left frontal 1.55  ± 0.11 1.44  ± 0.08 0.040 
Right frontal 1.52  ± 0.10 1.41  ± 0.06 0.012 
Left temporal 1.40  ± 0.10 1.36  ± 0.08 0.343 
Right temporal 1.41  ± 0.09 1.37  ± 0.08 0.344 
Left parietal 1.41  ± 0.07 1.37  ± 0.08 0.191 
Right parietal 1.39  ± 0.11 1.37  ± 0.12 0.585 
Left occipital 1.35  ± 0.10 1.31  ± 0.08 0.080 
Right  occipital 1.37  ± 0.09 1.33  ± 0.10 0.447 
Subcortical 1.16  ± 0.10 1.09  ± 0.08 0.134 







Figure 1. Sagittal (upper) and transversal (lower) 123I-
5I-R91150 SPECT images in one dog. Compared to 
the control images (A and B), 5-HT2A receptor 
availability was decreased after morphine pre-treatment 
(C and D) in the frontal cortex (delineated region). 
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E. Discussion 
 A 123I-5-I-R91150 SPECT study was conducted in dogs to examine the influence of a 
single intravenous bolus of morphine on 5-HT2A binding and a decline in 5-HT2A receptor 
availability was observed in the frontocortical region in dogs treated with morphine 
compared to the untreated group.  
The BIs were only decreased significantly in the frontal cortex even though there was an 
overall decreased 5-HT2A receptor binding after morphine treatment (Figure 1). Both MOR 
and 5-HT2A receptors are widely distributed throughout the cortex (Tempel and Zukin, 1987; 
Blue et al., 1988). The frontal cortex, however, is known to be a region with both high MOR 
and 5-HT2A receptor expression (Tempel and Zukin, 1987; Blue et al., 1988). The 
frontocortical region is involved in the control of the cognitive and emotional aspects of pain. 
MOR analgesics do not only exert their action through peripheral and spinal MOR activation, 
which alters the transmission of the noxious stimulus, on top of this, central MOR activation 
influences the perception of pain. Therefore, the frontal cortex is, not surprisingly, rich in 
MORs. In the frontal cortex 5-HT2A receptors are well represented as well (Tempel and 
Zukin, 1987; Blue et al., 1988). Frontocortical 5-HT2A receptors have been shown to play a 
role in several mood disorders, such as anxiety, aggression and depression not only in 
humans (Nic Dhonnchadha et al., 2003; Mintun et al., 2004), but also in dogs (Peremans et 
al., 2003b; Vermeire et al., 2009). These are mood disorders that often arise during opioid 
addiction and dependence and a 5-HT dysfunction is suggested to represent a main 
mechanism contributing to mood disorders in opiate abstinence (Goeldner et al., 2011). 
Additionally, 5-HT2A receptor blockade is thought to restore some of the neurochemical 
modifications induced by long-term use of drugs of abuse, such as morphine (Lanteri et al., 
2008). 
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The decreased 5-HT2A receptor BIs found in the frontal cortex could be due to morphine-
induced 5-HT release in the cortex, hence competing or interfering with 5-HT2A radioligand 
binding. MOR agonists affect, next to their direct inhibitory action on neurons, several other 
neurotransmitter systems that contribute to opioid effects. One of these neurotransmitter 
systems is the 5-HTergic system, greatly involved in mood regulation. It has been well 
established that the analgesic action of morphine relies in part on the activation of descending 
bulbospinal 5-HTergic fibers. Supraspinal MOR activation by morphine leads to 5-HT 
release in the spinal cord (Bardon and Ruckebusch, 1984). Supraspinal MOR activation also 
causes increased 5-HT levels in several brain regions (Tao and Auerbach, 1994). In rodents 
for instance, systemic morphine increased extracellular 5-HT in the frontal cortex (Tao and 
Auerbach 1995). Another sequel of the increased synaptic 5-HT release could be 
downregulation and/or internalization of the 5-HT2A receptor. However, the in vitro study 
from Van Oekelen and colleagues demonstrated that cell pre-treatment with 5-HT for 15 
minutes and 48 hours did not provoke reduced 5-HT2A receptor numbers (Van Oekelen et 
al., 2001). This pleads against down-regulation or internalization of the 5-HT2A receptor by 
morphine invoked release of 5-HT. 
Furthermore, it has been demonstrated that both receptors share a common intracellular 
pathway involving protein kinase C activation (López-Giménez et al., 2008). The latter study 
additionally reported that 5-HT2A receptor activation resulted in a faster MOR 
desensitization, internalization and down-regulation (López-Giménez et al., 2008). By 
analogy, we might be tempted to interpret our results in a similar way, though the other way 
around, namely that MOR activation might increase 5-HT2A receptor downregulation and/or 
internalization. An interaction between both receptors on glutamatergic neurons located in 
the neocortex has been suggested by the findings of Marek and colleagues (Marek and 
Aghajanian, 1998b). 
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Both receptors appear to regulate glutamate release presynaptically: 5-HT2A receptor 
activation promotes glutamate release, whereas MOR activation inhibits this enhanced 
glutamate release (Marek and Aghajanian, 1998b). The glutamate release induced by 5-
HT2A receptor activation is thought to mediate a typical behavioral pattern of head shaking 
and twitching, which is seen after frontocortical 5-HT2A receptor activation (Willins and 
Meltzer, 1997). Accordingly, this behavior was attenuated after MOR agonist 
(buprenorphine, fentanyl) administration (Marek, 2003).  
It must be stated that this might not be the only cause for the lower BIs found. SPECT 
imaging is an elegant technique to quantify neurotransmitter systems in vivo, albeit a degree 
of caution is warranted when interpreting the images since the present findings may reflect 
other types of interactions as well. Direct interactions involving direct binding of morphine to 
the 5-HT2A receptor may be another possibility, since studies exist that reported direct 
interactions between opioids and 5-HTergic receptors. For instance, morphine was shown to 
interact with human 5-HT3A receptors (Wittmann et al., 2006), and fentanyl shows, albeit 
low, affinity for 5-HT1A receptors (Tao et al., 2003). To our knowledge however, no such 
interaction has been described for morphine and 5-HT2A receptors. 
In a recent study comparing the effects of morphine on serotonergic neurons in midbrain 
areas in the presence or absence of acute noxious stimulation, it was found that those 
serotonergic neurons responded differently to morphine when pain was present, i.e. they 
showed a higher neuronal activity (Bajic and Commons, 2010). The influence of morphine on 
the 5-HT2A receptor availability might be different in the presence of acute noxious 
stimulation. 
The interference of anesthetics with radioligand binding is another consideration that 
needs to be taken into account (Giron, 2009). However, both groups underwent the same 
anesthetic protocol, with the exception of the propofol dose, thus eliminating interference of 
Chapter 4: Acute morphine and cerebral 5-HT2A receptors in dogs 
	  	  
92 
anesthetics with radioligand binding as a possible confounding factor. Several studies on the 
influence of different anesthetic agents on the central serotonergic system have shown that 
isoflurane reduces 5-HT release (Mukaida et al., 2007), whereas propofol increases synaptic 
5-HT levels by blocking the 5-HT transporter, SERT (Zhao and Sun, 2008). In the present 
study, the C group was administered more propofol compared to the M group. However, 
recent findings from our research group (unpublished data) suggested no difference in 5-
HT2A receptor binding between low and high propofol dosage, implying that the difference 
in propofol dosage between the two treatment groups in this study would be of minor 
importance. Additionally, we found that morphine did not influence the regional cerebral 
blood flow in dogs (Adriaens et al., 2013c), therefore this cannot account for the found 
changes in 5-HT2A receptor BIs.  
F. Conclusion 
Our findings support the existence of an interaction between morphine and 5-HT2A 
receptor binding in the canine frontal cortex. In the absence of pain and mood disorders, 
morphine decreased the 5-HT2A receptor availability. Future studies investigating the exact 
mechanism of this interaction would be of great interest, including the influence of morphine 
on SERT. Overall the present study supports the possible beneficial effect of 5-HT2A 
receptor drugs in the prevention of common opiate side effects such as dependence and 
addiction, as well as the use of opioids in mood disorders.  
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A. Abstract 
Drugs acting on the serotonergic 2A (5-HT2A) receptor, as well as opioids have been 
reported as augmenting agents in depression therapy. The present study examined the effect 
of prolonged opioid treatment on cerebral 5-HT2A receptors. 
Methods: Brain 5-HT2A receptor availability was estimated in seven healthy five-year-old 
female neutered Beagle dogs pre and post 10-day morphine treatment (oral sustained release 
morphine 20 mg twice daily for ten days) with 123I-R-91150, a 5-HT2A selective radioligand, 
and SPECT. 5-HT2A receptor binding indices (BI) for the frontal, parietal, temporal and 
occipital cortex and the subcortical region were calculated. Data were analyzed by mixed 
model with treatment as fixed effect and dog as random effect.  
Results: Morphine treatment significantly (P ≤ 0.05) lowered 5-HT2A BIs in the right and 
left frontal cortex, the right and left temporal cortex, the right  and left parietal cortex, and the 
subcortical region. 
Conclusion: The decreased cerebral 5-HT2A receptor availability following prolonged 
morphine exposure suggests an interaction between the opioid and serotonergic system, the 
exact nature of this interaction remains to be elucidated. 
  




Enhancing the synaptic availability of serotonin (5-HT) is one of the critical components 
of pharmacological treatment of depression and most antidepressant drugs act on the 
inhibition of serotonin re-uptake. As a result, selective serotonin reuptake inhibitors (SSRIs) 
are commonly used for the treatment of depression. However, long-term remission of 
symptoms cannot always adequately be maintained with the currently available 
antidepressant drugs (Nemeroff, 2007). Moreover, it takes several days to weeks before these 
antidepressants exert their full clinical effect. This lag-time in onset suggests that down-
stream neuronal adaptations are more likely to be responsible for the therapeutic effects of 
antidepressants, rather than the immediate synaptic 5-HT elevation itself (Manji et al., 2000).  
The last decade, more attention has been paid to the down-stream molecular effects 
occurring during depression and antidepressant treatment. It has been suggested that 
abnormalities in monoamine receptors and a relative deficiency of monoamines may lead to 
depression (Stahl, 2008). In depressed patients, adaptive upregulation of postsynaptic 
receptors, such as the serotonergic 2A (5-HT2A) receptor, has been observed (Cahir et al., 
2007; Shelton et al., 2009). Furthermore, 5-HT2A receptor expression has been shown to be 
altered after SSRI treatment in humans and dogs (Gray and Roth, 2001; Peremans et al., 
2005). Atypical antipsychotics with 5-HT2A receptor antagonist properties have been shown 
to augment the therapeutic effect of SSRIs (Ostroff and Nelson, 1999; Marek et al., 2003; 
Philip et al., 2008; Nelson and Papakostas, 2009). Therefore, the postsynaptic 5-HT2A 
receptor is thought to be a possible target for antidepressant therapy.  
Mu opioid receptor (MOR) agonists have been reported to increase serotonin levels in the 
brain (Tao and Auerbach, 1994) and in view of this, the use of opioids as additional 
antidepressant therapeutics has been investigated. Indeed, biochemical and behavioral studies 
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suggest the involvement of the opioid system in the mechanism of action of certain 
antidepressants (Fichna et al., 2007a). Additionally, opioids have been found to have 
antidepressant-like properties (Bodkin et al., 1995; Tejedor-Real et al., 1995; Besson et al., 
1996; Stoll and Rueter, 1999). However, the exact potential of opioids as antidepressant 
agents remains a matter of discussion.  
In previous studies we have shown that the dog can be used as a suitable model for 
humans for single photon emission computed tomography imaging (SPECT) of the 5-HT2A 
receptors using the radioligand 123I-R91150 (Peremans et al., 2003b; Vermeire et al., 2009). 
Additionally, we have previously demonstrated that a single dose of morphine lowered the 5-
HT2A receptor availability in the canine frontal cortex (Adriaens et al., 2012a).  
Since both opioids, like morphine, and 5-HT2A receptors appear to be involved in similar 
biological processes, the aim of the present study was to assess the influence of prolonged 
administration of morphine on the cerebral 5-HT2A receptors in dogs. 
C. Materials and Methods 
1. Animals 
Seven healthy Beagle dogs (neutered females), ranging in weight from 6.4 kg to 7.4 kg, 
and age from 3 to 4 years old were used in this study. None of the dogs had a history of 
previous major disease or neurological disorder. All procedures and protocols were approved 
by the Ghent University Ethical Committee (EC2010/152). 
2. Study Design 
Each dog underwent two SPECT scans. The first scan consisted of a baseline scan (pre-
morphine condition) to which data from the second scan (post-morphine condition) were 
compared. Post-morphine scans were performed after an opioid treatment that consisted of an 
oral sustained release formulation of morphine (20 mg morphine sulphate, MS Contin®, 
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Mundipharma, Mechelen, Belgium) administered orally twice daily for 10 days, which is 
comparable to a dosage of 2.86 ± 0.16 mg/kg twice daily. The dogs were monitored closely 
(respiratory rate, heart rate and quality, degree of sedation, nausea and emesis) for 3 hours 
after morphine administration and side effects were noted if observed. 
Food, but not water, was withheld for 12 hours before each scan. To check whether the 
given morphine dosage was clinically relevant, morphine plasma concentrations were 
determined. For this, 5 mL of blood were collected from the jugular vein and placed in a 
heparinized blood tube the last day of treatment 3 hours after the last morphine 
administration. Blood was centrifuged at 3500 rpm for 5 minutes after which plasma was 
collected and kept at -20 °C until analysis was performed. 
3. Tracer 
123I-R91150 is synthesized by electrophilic radioiodination on the 5-position of the 
methoxybenzamide group of R91150 (Eersels et al., 2005), followed by purification with 
high-performance liquid chromatography and was obtained from the Nuclear Medicine and 
PET research department of Nuclear Medicine and PET research of the VU University 
Medical Centre (Amsterdam, The Netherlands). The product had a radiochemical purity of 
more than 99 % and was sterile and pyrogen free. The administered radioligand had a 
specific activity of 370 GBq/µmol. The radioligand is a 5-HT2A antagonist with high affinity 
(Kd = 0.11 nM) and selectivity for the 5-HT2A receptor. The selectivity of the ligand for 5-
HT2A receptors with regard to other neurotransmitter receptors such as other 5-HT receptors, 
including 5-HT2C and 5-HT1A, dopamine receptors, adrenergic receptors and histamine 
receptors is at least a factor 50. The tracer is displaceable with ketanserin, a 5-HT2 antagonist 
(Catafau et al., 2006) and has been previously shown to be suitable for the use in dogs 
(Mertens et al., 1994; Peremans et al., 2002a).  
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4. Anesthetic Protocol 
All dogs were sedated prior to general anesthesia with intramuscular dexmedetomidine 
375 µg/m2 body surface area (Dexdomitor®, Orion Corporation, Espoo, Finland). After 
placing a 22-gauge intravenous (IV) catheter in the cephalic vein, anesthesia was induced 
with IV propofol (Propovet®, Abbott Laboratories, Queenborough, United Kingdom), 2.14 ± 
0.56 mg/kg for the pre-morphine condition and 1.86 ± 0.38 mg/kg for the post-morphine 
condition (mean ± SD). Anesthesia was maintained, after endotracheal intubation, with 
isoflurane (Isoflo®, Abbott Laboratories) (1.4% end tidal concentration) in oxygen using a 
rebreathing system. Acquisition started 10 minutes after induction of anesthesia. The dogs 
were mechanically ventilated by intermittent positive pressure ventilation to maintain 
eucapnia, i.e. end tidal CO2 within 35-45 mmHg, in order to limit the influence of the PaCO2 
on cerebral perfusion.  
5. Image Acquisition 
The dogs were positioned in ventral recumbency with fixation of the head in a preformed 
cushion, to prevent individual positioning artifacts. SPECT was performed with a triple head 
gamma camera (Triad Trionix, Twinsburg, OH, USA) equipped with ultrahigh resolution 
parallel hole collimators (FWHM of 8 mm). Images were acquired 90 minutes post injection 
of the radioligand, this is the moment at which pseudoequilibrium is present in dogs (21). 
Total acquisition time was 30 minutes. For each acquisition, 90 projection images were 
obtained on a 128x128 matrix using a step-and-shoot mode (20 s/step, 4° steps). Camera and 
table positioning were recorded to ensure optimal ‘intraindividual’ comparison. 
6. Image Processing 
The radioligand data were reconstructed using the HERMES HybridRecon program 
(HERMES Medical Solutions, Stockholm, Sweden). The reconstruction is based on an 
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ordered subset expectation maximization-based reconstruction algorithm with attenuation 
(using a CT transmission scan), collimator response and Monte Carlo-based scatter 
correction. The details of the reconstruction algorithm can be found in Sohlberg et al., 2008. 
Reconstructed images were post-filtered using a Butterworth filter (cut-off, 1.6 cycles/cm, 
order 5). 
The 123I-R91150 emission data were fitted to a template, that is based on previously 
obtained cerebral perfusion data, using multimodality software (version 5.0; Nuclear 
Diagnostic AB) (Peremans et al., 2003a). This software displays images in a dual-window 
setting and allows for manual co-registration by providing tools for scaling, rotating, and 
translating images in all 3 dimensions. The following volumes of interest (VOIs) were 
included: right and left frontal, temporal, parietal and occipital cortices, as well as the 
subcortical and cerebellar region. The cerebellum, a region with low densities of 5-HT2A 
receptors, is used as a reference region for non-specifically bound and free radioligand. 
Consequently, the measured radioactivity in the cortical regions represents the total activity, 
i.e. specific and non-specific bound and free radioligand. The binding index (BI) was 
calculated as ([counts per pixel in VOI] - [counts per pixel in cerebellum]) / (counts per pixel 
in cerebellum). This BI is proportional to the in vivo density of available receptors under 
pseudoequilibrium conditions (Pazos et al., 1987). 
7. Morphine Plasma Concentrations 
Plasma concentrations of morphine were determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method. The quantification was 
based on the use of codeine as an internal standard (IS), which was added to the homogenized 
plasma samples prior to analysis. Quality control (QC) and blank samples were analyzed 
together with each batch of incurred samples to check the extraction and LCMS/MS 
Chapter 5: Prolonged morphine and cerebral 5-HT2A receptors in dogs 
101 	   	  
procedure. All QC, blank and calibration curve samples were prepared in pooled drug-free 
dog plasma. After addition of 25 µL of the IS working solution of 10 µg/mL to 250 µL of the 
dog plasma samples, the pH was adjusted by addition of 500 µL of a 0.67 M aqueous 
phosphate buffer. After vortex mixing for 15 sec, the samples were put on an Oasis® MCX 
(mixed cation exchange) solid-phase extraction column (3 mL, 60 mg; Waters, Milford, MA, 
USA), previously conditioned with 2 mL of methanol and 2 mL of HPLC grade water. 
Subsequently, the column was washed with 2 mL of HPLC water, 1 mL of 0.1 M 
hydrochloric acid in water and 2 mL of methanol, respectively. Morphine and codeine were 
eluted with 2 mL of dichloromethane/2-propanol/ammonia (80/20/2, v/v/v). After 
evaporation at 50 °C under a gentle stream of nitrogen, the dry residue was dissolved in 100 
µL of 0.1% formic acid in HPLC water and filtered through a polyvinylidene fluoride 0.22 
µm filter (Millipore, Billerica, MA, USA). An aliquot of the extract (8 µL) was injected onto 
the LC-MS/MS instrument. The HPLC system consisted of an Acquity UPLC® instrument 
from Waters. The analysis of the extracts was performed on a BEH-C18 1.7 µm column (2.1 
x 50 mm; Waters), used in combination with a frit. A gradient elution with 0.1% formic acid 
in water (A) and acetonitrile (B) was performed (98% A/2% B, 0–2 min; 50% A/50% B, 2.1–
3 min; 98% A/2% B, 3.1– 8 min). A Quattro Premier® XE MS instrument from Waters was 
used, equipped with an ESI (electrospray ionization) source, operated in the positive ion 
MS/MS mode. The following ion transition was monitored and used for quantification: m/z 
286 > 165. The limit of detection of the method was calculated to be 1.27 ng/mL based on a 
signal-to-noise ratio of 3/1. The accuracy and precision were determined at 10.0 and 50.0 
ng/mL in dog plasma (n = 6). The accuracy fell within the range of - 20% to +10%, and 
precision was also within the maximum RSD values as set by the EU (Anonymous, 2002) 
The limit of quantification (LOQ) was defined as the lowest concentration in dog plasma for 
which the method was validated with an accuracy and precision that fall within EU 
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recommended ranges and was set at 5.0 ng/mL. Plasma concentrations below the LOQ were 
not included in the data analysis. 
8. Statistical Analysis 
Changes in 5-HT2A receptor binding before and after morphine treatment were compared 
using the mixed model with ‘treatment’ as fixed effect and ‘dog’ as random effect. Data are 
presented as mean ± standard deviation (SD). Level of significance was set at P < 0.05 and P 
< 0.0056 when correcting for multiple comparisons (Bonferroni). 
D. Results 
The 10-day morphine treatment was well tolerated by the dogs. At any point during 
treatment we recorded the following side effects: nausea (number of dogs, n = 1), vomiting (n 
= 1).  
Table 1 represents the 5-HT2A receptor BIs in the different VOIs for both conditions. 
Significantly lower (P < 0.05) BI values were found in the right and left frontal cortex, the 
right and left temporal cortex, the right and left parietal cortex and the subcortical region for 
the post-morphine condition compared to the pre-morphine condition (Table 1). After 
correction for multiple comparisons 5-HT2A receptor BIs were still significantly (P < 
0.0056) decreased in the left frontal cortex and the right parietal cortex after morphine 
treatment. The decreased 5-HT2A receptor density in the post-morphine condition of one dog 
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Figure 1. Sagittal 123I-R91150 SPECT images in 
one dog. Compared to the pre-morphine images (A), 
5-HT2A receptor availability was decreased after 10 
days of morphine treatment (B). 
 
Table 1. 5-HT2A receptor binding indices before and after chronic morphine treatment (20 mg/kg oral sustained 
release morphine sulphate, twice daily for 10 days) (mean ± SD).  
VOI Pre-morphine Post-morphine P 
Left frontal 1.60 ± 0.15 1.40 ± 0.11 0.004* 
Right frontal 1.61 ± 0.19 1.45 ± 0.10 0.038 
Left temporal 1.48 ± 0.17 1.34 ± 0.10 0.019 
Right temporal 1.51 ± 0.15 1.35 ± 0.10 0.026 
Left parietal 1.55 ± 0.18 1.36 ± 0.12 0.009 
Right parietal 1.56 ± 0.17 1.37 ± 0.18 0.004* 
Left occipital 1.46 ± 0.20 1.36 ± 0.18 0.175 
Right  occipital 1.47 ± 0.17 1.38 ± 0.15 0.237 
Subcortical 1.33 ± 0.18 1.19 ± 0.13 0.012 
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* P < 0.0056 (Bonferroni correction). 
The morphine plasma concentration from the post-morphine condition on day 10, 3 hours 
after the last morphine administration was found to be 29.8 ± 7.8 ng/ml. Individual 
concentrations are shown in Table 2.  
Table 2. Morphine plasma concentrations (ng/mL) on the last day of treatment, 3 hours after intake (20 mg/kg 











5-HT2A receptors have been thought to be involved in the therapeutic effect of certain 
antidepressant drugs. Since opioids potentially have antidepressant effects, the present study 
investigated whether a prolonged morphine administration would have an influence on the 5-
HT2A receptor density. It was found that a 10-day morphine treatment decreased the 5-
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HT2A receptor availability in the majority of the canine cerebral regions measured with 
SPECT by means of the 5-HT2A receptor radioligand 123I-R91150. 
Traditionally, antidepressant therapy is based on increasing monoamine levels in the brain, 
5-HT in particular, resulting in adaptive down-regulation of post-synaptic receptors, such as 
the 5-HT2A receptor (Klimek et al., 1994; Gray and Roth, 2001; Meyer et al., 2001; 
Peremans et al., 2005). It has therefore been suggested that the effect of antidepressants on 
the 5-HT2A receptor contributes to their therapeutic effect. This hypothesis is confirmed by 
several studies on the use of atypical antipsychotics with 5-HT2A receptor antagonist 
properties as antidepressant therapy augmentation agents (Philip et al., 2008; Nelson and 
Papakostas, 2009). The results of our study demonstrate a decreased 5-HT2A receptor BI 
after 10 days of morphine treatment. These results are in line with the decreased 5-HT2A 
receptor density that was reported in dogs after 6-weeks of SSRI treatment, together with 
reduced impulsive aggression (Peremans et al., 2005). This behavioral improvement 
associated with the 5-HT2A receptor down-regulation underlines the clinical relevance of the 
observed findings. 
Morphine is a potent mu opioid receptor (MOR) agonist and since MORs and their 
endogenous ligands, such as endomorphins, are localized in brain regions involved in 
depression, it has been suggested that the endogenous opioid system could play a role in the 
pathogenesis of depression (Fichna et al., 2005a). For instance, the antidepressant-like effects 
of endomorphins in rodents was found to rely on their action on MORs (Fichna et al., 2007b). 
MOR agonists have been shown to produce a significant antidepressant effect not only in 
rodent models of depression, but also in humans suffering from treatment-refractory 
depression (Tejedor-Real et al., 1995; Bodkin et al., 1998; Stoll and Reuter 1999).  
The interaction between the serotonergic and opioid system has been extensively studied 
not only in the search towards new antidepressants but even more in the field of analgesia. 
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Modulation of the serotonergic system (e.g. by re-uptake inhibition) has been investigated in 
search for augmentation of the analgesic efficacy of opioids and the use of antidepressants is 
one of the well-established treatment options for chronic pain (Vadalouca et al., 2006; Banks 
et al., 2010). In this light, the 5-HT2A receptor is an interesting subject. Frontocortical 5-
HT2A receptors are thought to be involved in several mood disorders, such as anxiety, 
aggression and depression both in humans and dogs (Nic Dhonnchadha et al., 2003; 
Peremans et al., 2003; Mintun et al., 2004; Vermeire et al., 2009). Such mood disorders often 
occur during opioid addiction and dependence as well, and a 5-HT dysfunction is suggested 
to represent a main mechanism contributing to mood disorders in opiate abstinence (Goeldner 
et al., 2011). Additionally, blocking 5-HT2A receptors is thought to restore some of the 
neurochemical modifications induced by the long-term use of drugs of abuse, such as 
morphine (Lanteri et al., 2008). Even though our animals were not physically dependent on 
morphine, our results are in line with the previously mentioned findings that not only there is 
a serotonergic component in chronic opioid side effects, but that, more specifically, the 5-
HT2A receptor might be involved as well. Hence, the present findings could be of interest for 
future studies on opioid side effects.  
The morphine plasma concentrations determined in this study correspond to the clinically 
relevant concentrations found in literature (Dohoo, 1997). To achieve physical dependence or 
tolerance to morphine, higher dosages are needed (Yoshimura et al., 1993). However, this 
was not the goal of this study. Moreover, the use of opioids as potential antidepressant agents 
would be severely hindered due to side effects if high doses were required.  
The exact mechanism by which morphine decreases the 5-HT2A receptor availability in 
our study, remains to be elucidated. SPECT imaging is an excellent technique for visualizing 
and semi-quantifying neurotransmitter systems in vivo, however, it cannot provide tangible 
answers on the exact mechanisms that underlie the alterations in receptor binding. Since 
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morphine was administered during 10 days, an increased 5-HT tone could account for an 
adaptive down-regulation of the 5-HT2A receptors. An acute surge (15 minutes to 48 hours) 
in 5-HT could not provoke reduced 5-HT2A receptor numbers (Van Oekelen et al., 2001), 
however, chronic SSRI treatment in humans resulted in decreased 5-HT2A receptor density 
(Meyer et al., 2001). This was also seen in dogs, where 6 weeks of inhibition of serotonin 
reuptake resulted in decreased cortical 5-HT2A receptor binding (Peremans et al., 2005). 
Albeit 5-HT release was found to be reduced in morphine dependent rodents (Jolas et al., 
2000), as stated previously, the dogs used in the present study were not considered to be 
dependent on morphine. This possibly implies a different alteration of the serotonergic 
system during opioid dependency compared to prolonged low-dose opioid use.  
Another possible explanation for the morphine-induced decrease in 5-HT2A receptor 
binding could be an interaction between the MOR and 5-HT2A receptor. Both receptors are 
widely distributed in the brain (Tempel and Zukin, 1987; Blue et al., 1988) and it has been 
shown that 5-HT2A receptor activation influences MOR internalization, probably through a 
common intracellular pathway (López-Giménez et al., 2008). Thus it might be possible as 
well that MOR activation influences 5-HT2A receptor internalization and down-regulation. 
Competition between the radioligand and morphine for the 5-HT2A receptor could also 
occur, however, the affinity of morphine for the 5-HT2A receptor is rather low (Leysen et al., 
1982). Possible allosteric changes of the 5-HT2A receptors due to morphine binding would 
also be an interesting subject for future studies.  
F. Conclusion 
Prolonged exposure to morphine decreased the 5-HT2A receptor availability in a large 
part of the canine cortex. This finding gives further evidence for the existence of an 
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interaction between the opioid and 5-HT2A receptor system and encourages further research 
on the possible beneficial effects of opioids in the treatment of mood disorders. 
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In the following section, the results of the present doctoral thesis (Figure 1) will be discussed 
and compared to the existing literature. Additionally, study limitations and future prospects 
will be considered. 
 
Figure 1. Schematic overview of the findings of the different research studies. On the left, an overview of the 
applied volumes of interest in two directions. On the right the results from the research studies. A: the effect of a 
single dose of morphine on regional cerebral blood flow (rCBF) at 30 minutes post-morphine (A1) and 120 
minutes post-morphine (A2). B: the effect of prolonged morphine administration on rCBF. C: the effect of a 
single dose of morphine on the 5-HT2A receptors. D: the effect of prolonged morphine administration on the 5-
HT2A receptors. F: frontal cortex, P: parietal cortex, O: occipital cortex, T: temporal cortex, SC: subcortical 
region, C: cerebellum.  
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A. Morphine and canine brain function 
The first part of the present work investigated the effect of morphine on canine regional 
cerebral blood flow (rCBF) and, by analogy, brain function. The study regarding the effect of 
an acute administration of morphine (single intravenous dose of 0.5 mg/kg) on rCBF revealed 
two findings: alterations were found in the frontoparietal and subcortical region, and these 
changes in rCBF seemed to be time-dependent. Indeed, the decreased perfusion in the frontal 
cortex and the increased perfusion in the parietal cortex and subcortical region were only 
significant when comparing the data from 30 minutes after morphine administration to the 
baseline data. Prolonged administration of morphine (oral administration of 20 mg twice 
daily for 10 days), however, did not induce significant changes in rCBF, even though a trend 
of increased perfusion was found in the subcortical region.  
The “acute” study revealed changes in cerebral perfusion in regions that are known to be 
part of pain processing, and additionally, that have been shown to be involved in opioid 
effects. The subcortical region contains important structures such as the brainstem and the 
thalamus. Both these brain structures play a key role in nociception and antinociception. The 
thalamus is a relay center for painful stimuli to be further processed by cortical regions and is 
therefore involved in the sensory-discriminative as well as the affective-motivational aspects 
of pain (Treede et al., 1999). The brainstem on the other hand, contains important structures 
for the descending control of pain. Both the thalamus and the brainstem were found to be 
activated or deactivated by pain and/or opioids (Wagner et al., 2007; Adler et al., 1997; 
Zelaya et al., 2012; Khalili-Mahani et al., 2011; Peyron et al., 2000; Casey et al., 1996; Casey 
et al., 2000). The changes observed in the left (and although not significant, right) parietal 
cortex are consistent with the activation of this region following a painful stimulus or opioid 
administration (Wagner et al., 2001; Peyron et al., 2000). The frontoparietal region is thought 
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to be involved in the attentional and associative components of pain processing (Ohara et al., 
2005) and not surprisingly, brain activity in this region was altered in studies on pain and 
opioids (Wagner et al., 2001; Firestone et al., 1996; Khalili-Mahani et al., 2011; Adler et al., 
1997). Accordingly, a study investigating the effects of remifentanil on canine cerebral blood 
flow, found a decreased blood flow in the forebrain (Hoffman et al., 1993). 
The seemingly time-dependent action of opioids on cerebral activity has been proposed 
before. In a study in dogs using remifentanil, it was seen that cerebral blood flow and 
electroencephalogram values returned to baseline values after 30 minutes (Hoffman et al., 
1993). Remifentanil is a short-acting opioid, morphine on the other hand is a long-acting 
opioid, which could account for the delay in return to baseline values. Clinically, morphine is 
administered every 4 hours approximately, meaning that 2 hours after morphine 
administration, a clinical analgesic effect is still present, however, not visible in brain activity 
alterations. It is known that on top of its supraspinal action, morphine acts spinally as well as 
peripherally. Possibly the effects of morphine are more pronounced in the latter two areas as 
compared to the brain. Another possible explanation is the fact that once the MORs are 
activated by morphine, the downstream effects can linger on. A study investigating the 
temporal effects of remifentanil in rats suggested that the temporal response to remifentanil 
reflected underlying neurobiological processes (Liu et al., 2007). However, downstream 
effects (such as activation of other neurotransmitter systems) also require increased blood 
flow and oxygen supply, which does not match the observed lack of brain activity changes at 
2 hours post-morphine, making this assumption less plausible. Future studies should look into 
this aspect further, adding more scanning time points. 
In the “prolonged” study we failed to detect statistically significant changes in rCBF. Even 
though it is not advised to directly compare data obtained with 99mTc-ECD to 99mTc-HMPAO, 
it does correlate to the findings from the acute study, where no changes in rCBF were 
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detected 2h after morphine administration. However, the subcortical region did show a trend 
towards an increased perfusion after prolonged morphine administration. As mentioned, the 
subcortical region is important for pain processing and pain modulation. In this study we 
attempted to recreate an everyday situation using clinically relevant morphine doses and for a 
period of time that reflects a typical postoperative period necessitating analgesia. In research 
studies on the long-term effects of morphine and other opioids, the focus was mainly put on 
tolerance, addiction and dependence, which was not the aim of the study. Therefore, the 
results of our study are difficult to compare to those found in literature. Additionally, those 
addiction imaging studies are characterized by a great variation in study design, resulting, not 
surprisingly, in varying outcomes.   
B. Morphine and the canine 5-HT2A receptor system 
The second part of the present work investigated the possible effect of morphine on the 
canine cerebral 5-HT2A receptor system. First, a single acute morphine dose was 
administered which generated a decreased 5-HT2A receptor binding in the frontal cortex. In 
the second study, a prolonged exposure to morphine also decreased 5-HT2A receptor binding 
in the frontal cortex, and, additionally, in the temporal and parietal cortices and the 
subcortical region. It is important to note that the observed changes were not merely due to 
alterations in tracer delivery due to morphine-induced blood flow changes since the rCBF 
studies provide evidence that morphine does not influence regional brain perfusion at these 
time points.  
 In the “acute” study, we observed a decreased 5-HT2A receptor binding in the frontal 
cortex. 5-HT2A receptors are widely distributed throughout the cortex, with particularly high 
densities in the frontal area (Pompeiano et al., 1994; Burnet et al., 1995; López-Giménez et 
al., 1998; Hall et al., 2000; Amargós-Bosch et al., 2004). The MOR as well is highly 
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concentrated in the frontal cortex and both receptors have been shown to be co-expressed in 
frontocortical layer VIb (López-Giménez et al., 2008). The exact reason for the decreased 
binding in the frontal cortex cannot be determined by the present results, however several 
theories can be proposed. First, it is well established that morphine analgesia relies in part on 
the serotonergic system. Morphine increases 5-HT release in several brain regions and this 
increase in synaptic 5-HT might result in two distinct receptor mechanisms: desensitization 
and down regulation. Desensitization is a rapid process that follows activation of a receptor 
by an agonist, this can be homologous (by the receptor ligand, in this case 5-HT) or 
heterologous (by a ligand that binds to another GPCR, in this case morphine) (Gray and Roth, 
2001; Van Oekelen et al., 2003). 5-HT2A receptor desensitization has been observed in vitro 
as soon as 15 minutes after 5-HT exposure (Van Oekelen et al., 2001). Heterologous 
desensitization has been described for the MOR and 5-HT2A receptors, namely, MOR 
receptors were co-activated when 5-HT2A receptors were activated by 5-HT (López-
Giménez et al., 2008). In the present study, this might be interpreted the other way around 
with morphine being the co-activator/heterologous desensitizer for the 5-HT2A receptor. 
However, the radioligand used in the present studies is a neutral antagonist that binds to both 
the active receptor and the inactive (or desensitized) receptor. The radioligand can therefore 
not distinguish between both receptor states and thus 5-HT2A receptor desensitization is less 
likely to be a plausible explanation for our findings. Another possibility is the down 
regulation of the 5-HT2A receptor following 5-HT release. This is a slow process that leads 
to a decreased number of receptors on the plasma membrane, typically following repeated 
exposure to an agonist. However, in the same study of Van Oekelen and colleagues, it was 
demonstrated that cell treatment with 5-HT for 15 minutes and 48 hours did not result in 
decreased 5-HT2A receptor numbers (Van Oekelen et al., 2001). Direct binding of morphine 
to 5-HT2A receptors could also be possible since similar interactions between other MOR 
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agonists and 5-HT receptors have been described (Wittmann et al., 2006; Tao et al., 2003). 
However, the affinity of morphine for the 5-HT2A receptor is rather low (Leysen et al., 
1982). Conformational changes in the 5-HT2A receptor is another possibility, causing a 
decreased affinity for the radioligand. Receptor heterodimerization is less likely since the 5-
HT2A receptor and the MOR do not share a common cellular distribution (López-Giménez et 
al., 2008). 
In the “prolonged” study decreased 5-HT2A receptor binding was seen in almost the entire 
canine brain. This suggests that prolonged morphine has a greater impact on the serotonergic 
system. Additionally, prolonged or repeated exposure of GPCRs to their agonists leads to 
receptor down regulation due to increased receptor internalization and degradation. This has 
been observed for the 5-HT2A receptor following prolonged agonist exposure in several in 
vivo and in vitro studies (review: Van Oekelen et al., 2003). In the treatment of 5-HT-related 
brain diseases such as depression, a prolonged period of treatment is usually required in order 
to obtain a sufficiently high 5-HT tone. This is because the increased 5-HT tone in itself is 
not the key to treatment, but rather the downstream neuronal adaptations that result from 
these increased synaptic 5-HT levels, such as decreased 5-HT2A receptor numbers (Manji et 
al., 2000; Stahl, 2008). In depressed patients, adaptive upregulation of postsynaptic receptors, 
such as the 5-HT2A receptor, has been observed (Shelton et al., 2009) and a decreased 
number of 5-HT2A receptors is seen after antidepressant treatment both in humans and dogs 
(Gray and Roth, 2001, Peremans et al., 2005).  
As mentioned, MOR agonists are known to increase brain 5-HT levels, thus mimicking 
the effect of common antidepressant drugs like selective serotonin reuptake inhibitors 
(SSRIs). This raised the question whether opioids could be potential antidepressants in 
addition to traditional treatment that does not always provide full recovery. Indeed, 
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biochemical and behavioral studies suggest the involvement of the opioid system in the 
mechanism of action of certain antidepressants (Fichna et al., 2007b). Additionally, opioids 
have been found to have significant antidepressant-like properties in both rodent models of 
depression and in humans suffering from treatment-refractory depression (Bodkin et al., 
1995; Tejedor-Real et al., 1995; Stoll and Reuter, 1999). However, the exact potential of 
opioids as antidepressant agents remains a matter of discussion. In a recent PET imaging 
study designed to map connections between neurotransmitter systems, regionally specific 
intercorrelations were observed between the opioid and serotonin system in regions that are 
known to play a role in several neuropsychiatric diseases (Tuominen et al., 2013). Our results 
contribute to this knowledge, given that 5-HT2A receptor binding was decreased after 
morphine treatment (both “acute” and “prolonged”), which is one of the objectives of the 
treatment of neuropsychiatric disease with a 5-HT2A receptor component (e.g.: effect of 
antidepressants on 5-HT2A: Meyer et al., 2001; antidepressants augmented by atypical 
antipsychotics: Philip et al., 2008). 
With regards to the role of the serotonergic system – and the 5-HT2A receptor in 
particular – in opioid effects and side effects, our results support the existence of a link 
between the two systems (opioid and serotonergic) and provide ground for further 
investigation into the specific role of the 5-HT2A receptor in this interaction. To enhance the 
therapeutic effects of opioids, one possible option is to target other neurotransmitter systems 
that are involved in opioid analgesia, such as the serotonergic system. Adding antidepressants 
that augment cerebral 5-HT levels is one option that has been proven successful (Nayebi et 
al., 2009; Banks et al., 2010); specifically targeting certain 5-HT receptors is another. In the 
light of the present results and given that 5-HT2A receptor antagonists have been seen to 
have analgesic properties (Nishiyama, 2005), the 5-HT2A receptor might be one of those 
targets. As for the role of the 5-HT2A receptor in long-term opioid side effects, results are 
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not that straightforward. Sandrini and colleagues found that although morphine and 
paracetamol decreased 5-HT2 receptor binding, only morphine induced tolerance in vivo 
suggesting that the 5-HT2 receptors were not involved in the development of tolerance 
(Sandrini et al., 2007). On the other hand, López-Giménez and colleagues found that 5-HT2A 
receptor co-activation in vitro reduces morphine tolerance by co-activation of intracellular 
pathways (López-Giménez et al., 2008). In addition, since morphine causes 
abnormal/diminished internalization of the MOR (see introduction), promoting MOR 
internalization could be an important tool to counter the development of tolerance, as was 
observed by López-Giménez and colleagues (López-Giménez et al., 2008). In this light, our 
results give further hints towards that end, as there appears to be a visible link between both 
systems. With regards to addiction, 5-HT2A antagonists were found to prevent the 
hyperreactivity of the serotonergic and noradrenergic system associated with repeated 
administration of drugs of abuse such as morphine (Lanteri et al., 2008). 
C. Methodological considerations 
Two different brain perfusion tracers were used for the studies on the effects of morphine 
on canine brain function, namely 99mTc-ECD for the acute study and 99mTc-HMPAO for the 
prolonged study. As mentioned in the introduction of this thesis, both of these perfusion 
tracers are commonly used in human investigations, however, until recently, 99mTc-ECD was 
mainly used in canine studies. Due to the suspended production of 99mTc-ECD, we 
investigated the possibility of using 99mTc-HMPAO as an alternative for 99mTc-ECD. Since 
studies in human research found differences in cerebral distribution patterns between both 
tracers, we investigated this question in dogs. Indeed, comparison of those perfusion tracers 
in dogs revealed regional differences. The use of 99mTc-ECD resulted in a higher perfusion 
index in the subcortical region compared to 99mTc-HMPAO. On the other hand, the perfusion 
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index was significantly lower in the cerebellum in the 99mTc-ECD data compared to the 
99mTc-HMPAO data. These data support the use of both tracers for cerebral perfusion 
evaluation in dogs, however, they are not interchangeable and direct comparison is not 
always advised. Additionally, since the cerebellum is commonly used as a reference region 
for semiquantification purposes, the difference in uptake between both tracers is of great 
importance and semiquantification using the entire brain as a reference region is more 
reliable. 
There are six concerns that need to be addressed with regards to the present work: the 
pharmacokinetics of oral morphine in dogs, the so-called prolonged 10-day morphine 
treatment, the absence of pain in the dogs, the need for anesthesia during scanning, the 
gender, and the clinical relevance of the present findings.  
In the studies investigating the effect of prolonged administration of morphine on the 
canine brain, this prolonged treatment consisted of an oral sustained release formulation of 
morphine (20 mg morphine sulphate, MS Contin®, Mundipharma, Mechelen, Belgium) 
administered orally twice daily for 10 days, which is comparable to a dosage of 2.37 ± 0.25 
mg/kg (perfusion study) and 2.86 ± 0.16 mg/kg (5-HT2A receptor study) twice daily. The 
oral bioavailability of morphine in dogs is poor due to the first pass elimination by liver and 
intestinal mucosa with the liver being the major site of morphine metabolization in dogs 
(Merrell et al., 1990). Therefore, morphine concentrations were measured in plasma (both 
studies) and in cerebrospinal fluid (CSF) (only in the perfusion study) to ensure adequate 
dosage. In the brain perfusion study, mean plasma concentrations were 47.60 ± 9.74 ng/mL 
and mean CSF concentrations were 9.53 ± 3.12 ng/mL. In the 5-HT2A receptor study, mean 
morphine plasma concentrations were 29.8 ± 7.8 ng/ml. These concentrations are comparable 
to the concentrations described in dogs that are clinically relevant – i.e. that produce 
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analgesia – after similar treatment (Hug, 1981; KuKanich et al, 2005; Dohoo, 1997). As was 
described in the study by Dohoo, we also found a high intersubject variability (Dohoo, 1997). 
For the duration of the prolonged morphine administrations, we attempted to recreate a 
situation that was close to everyday clinical settings, where postoperative pain management 
requiring opioids rarely exceeds 10 days. It is important to underline that we did not attempt 
to induce tolerance in those dogs, as higher doses or a longer period would have been needed 
(Yoshimura et al., 1993). Additionally, tolerance would have needed to be assessed by other 
methods, such as measuring paw withdrawal latencies after a painful stimulus, in order to be 
certain that tolerance to morphine was present. This leads us to another important reflection, 
the fact that the dogs in the present studies were non-painful dogs. As mentioned in the 
introduction chapter, chronic pain can cause functional as well as structural alterations. 
Taking this into consideration, painful dogs could respond differently to morphine and show 
different imaging results. 
As mentioned in the introduction, imaging studies in animals have one important 
disadvantage, the need to immobilize them in order to be able to perform the image 
acquisition. This is mainly achieved by anesthetizing the animals. This could possibly have 
an influence on the neurotransmitter system under observation and additionally on cerebral 
blood flow, with potential influence on the distribution of the radioactive tracer. These 
influences always need to be taken into account when interpreting the obtained data. Studies 
from our research group have examined the impact of several anesthetics on brain function 
and the 5-HT2A receptor system. To put in a simple way, the following overall conclusions 
can be drawn from these studies. For the brain function studies: since the tracer provides a 
fixed image because it is trapped in the brain cells within 2 minutes, all drugs administered 
after the plateau is reached have no influence on the data. For the 5-HT2A receptor studies: 
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the type of anesthetics have to be considered in function of their possible interaction with the 
5-HT system, and second, as long as we adhere strictly to the same anesthetic protocol, 
differences observed between two study groups should be due to the interfering factor (in the 
present case: the administration of morphine).  
In this line, it is also important to work with homogeneous groups of subjects. Sex 
differences are known to exist in nociception and in the response to opioids (Kest et al., 2000; 
Hurley et al., 2008). We opted for neutered female dogs since this would overcome the cyclic 
hormonal influences of intact female dogs. However, morphine appears to be less potent in 
females (Loyd et al., 2008), thus it would be interesting for future studies to compare the 
present results to new studies in male dogs as the finding might be more pronounced. Ageing 
has been shown to have an influence on cerebral 5-HT2A receptors; therefore, it is advised to 
use groups with similar ages (Baeken et al., 1998; Peremans et al., 2002).  
Last but certainly not least, it is important to be able to determine the clinical relevance of 
our findings. Statistically significant does not always mean clinically relevant and vice versa. 
This is difficult to assess correctly, often requiring an extra dimension to the obtained 
imaging results, such as behavioral data. For the 5-HT2A receptors indeed, a study on canine 
impulsive aggression revealed improvement of the aggressive behavior after treatment, 
together with decreased 5-HT2A receptor binding (Peremans et al., 2005). The magnitude of 
the differences in binding was comparable to those in the present studies, providing solid 
ground for the clinical relevance of our results.  
D. Conclusions and future studies 
We investigated the influence of morphine on the canine brain, more specifically, on 
cerebral perfusion and 5-HT2A receptors. As expected, morphine altered the brain perfusion, 
and thus, brain function. Unexpectedly, these changes appear to be time-dependent. In 
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addition, morphine alters 5-HT2A receptor availability. This was more pronounced in the 
prolonged study thus emphasizing the 5-HT2A-opioid interaction, which could be of 
importance for mood disorder treatment on the one hand and opioid long-term side effects on 
the other hand. 
The present work underlines the value of brain imaging in drug research and strengthens 
the use of SPECT in dogs. An important aspect of drug research is inevitably the need for 
animal models and providing in vivo models that give a maximum of information with the 
least amount of discomfort, which is achievable with brain imaging studies. To progress in 
drug research it is important to first gain as much knowledge as possible on the presently 
available drugs so that a complete image is created, which can be used as a soundboard for 
new discoveries. To gain insights into the modes of action of a protagonist opioid such as 
morphine is therefore of great value and future studies on the topic should be considered.  
Future imaging studies could include comparing the rCBF pattern of morphine to patterns 
generated by other opioids. These studies could also include shorter time intervals between 
scans to further investigate the temporal differences seen with morphine. Other dosing 
protocols could also provide valuable information. In this light, inducing morphine tolerance 
could be an interesting research path to elaborate, which can be combined with a behavioral 
component, such as paw withdrawal latency tests, to assure tolerance is present. On the other 
hand, seeing as other neurotransmitter systems are closely involved in the working 
mechanism of opioids, it could be interesting to look at their reaction to morphine. For 
instance, dopamine is known to be an important factor in opioid side effects and the influence 
of prolonged morphine administration on the dopaminergic system could be investigated.  
Next to studies in healthy dogs, dogs suffering from chronic pain could also provide 
important information. Chronic pain does not only have a debilitating effect due to the 
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ongoing pain, it also has an impact on mental health. Depression is often seen in patients with 
chronic pain. Therefore, rCBF and 5-HT2A receptor availability could be assessed in these 
patients as well as the influence of opioids and other drugs. Ketamine, for instance, is used as 
an analgesic – interestingly, as an adjunct to opioid therapy as well – and has been shown to 
possess antidepressant properties (review: Murrough, 2012). In a previous study from our 
research group, ketamine was found to decrease 5-HT2A receptor availability in the frontal 
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Regional cerebral blood flow (rCBF) is known to be a measure for regional brain activity. 
Therefore, it can be used to determine how a drug works by examining the rCBF pattern it 
produces. On top of this, different drugs can be compared by comparing their rCBF patterns. 
In the case of analgesics, it is interesting to compare the possibly different loci of activity 
depending on the analgesic drug. To evaluate rCBF in dogs, previous studies have used 
99mTc-ECD single photon emission computed tomography (SPECT). However, in human 
medicine, 99mTc-HMPAO has also been frequently used in brain imaging studies. Therefore, 
the first aim of the present doctoral thesis was to compare both 99mTc-ECD and 99mTc-
HMPAO for rCBF evaluation in dogs. 
1. The comparison of rCBF evaluation with 99mTc-ECD and 99mTc-HMPAO in dogs 
The aim of the first study was to examine whether regional distribution differences 
between both tracers occur in dogs as is reported in humans. Eight beagles underwent two 
SPECT examinations first with 99mTc-ECD and followed by 99mTc-HMPAO. Changes in 
rCBF between both tracers were found in the subcortical (P = 0.001, ECD > HMPAO) and to 
a lesser extent in the cerebellar region (P = 0.03, ECD < HMPAO). This study shows that 
both tracers can be used for the visualization of the canine cerebral blood flow. However, due 
to differences in regional distribution, a selection of either 99mTc-ECD or 99mTc-HMPAO 
should be made and, most importantly, direct comparison between both tracers is not 
recommended. 
A prototypical analgesic drug frequently used in both veterinary and human medicine is 
the mu opioid receptor (MOR) full agonist, morphine. It is widely used in cases of acute pain 
such as perioperative pain management. The aim of the second section of this doctoral thesis 
was therefore to examine the effect of morphine on the canine rCBF to gain insights on how 




2. The influence of a single dose of morphine on canine rCBF 
The aim of the second study was to determine whether a single intravenous bolus of 
morphine (0.5 mg/kg) alters rCBF. This experimental randomized cross-over study was 
conducted in 8 beagle dogs. Three SPECT scans were performed using 99mTc-ECD: Baseline, 
30 minutes after morphine and 120 minutes after morphine. We found a significant increase 
in rCBF in the subcortical region and the parietal region and a decrease in the frontal region 
in the scan 30 minutes after morphine compared to the baseline values. The subcortical 
region includes structures important for pain modulation (inhibition) and therefore it is not 
surprising that an analgesic would increase brain activity in this region. However, we could 
not find differences 120 minutes after morphine. This could possibly imply a time-dependent 
mode of action of morphine, which would be interesting to investigate more thoroughly in 
future studies. 
3. The influence of prolonged morphine administration on canine rCBF 
The aim of the third study was to evaluate the effect of a 10-day morphine treatment on 
cerebral perfusion. We conducted a randomized cross-over study in 8 beagle dogs. Two 
SPECT scans were performed to evaluate the rCBF using 99mTc-HMPAO: Baseline and after 
10 days of morphine treatment (20 mg twice daily, oral sustained release morphine sulphate). 
Morphine plasma concentrations were also determined on the last day of treatment to 
evaluate whether the administered morphine dose was sufficient. Comparison of the Baseline 
and the morphine perfusion failed to reveal significant differences. Plasma concentrations 
were comparable to those in literature and are considered to be clinically relevant. 
An interaction between the opioid and serotonergic system has long been described. 
Indeed, opioids can increase serotonin (5-HT) levels in the spinal cord (descending pain 
inhibition) but also in the brain. This interaction at a supraspinal level is important not only 
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for the analgesic properties of opioids, but it can also account for 1) the possible 
antidepressant effect of opioids (increasing serotonin levels is a key component of 
antidepressant therapy), and 2) the development of long term side effects of opioids 
(downstream alterations of neurotransmitter systems is an important causal effect). More 
specifically, the 5-HT2A receptor has been reported to play a role in analgesia, depression 
and in the development of opioid side effects. Therefore, the aim of the third section of this 
thesis was to investigate the influence of morphine in the canine cerebral 5-HT2A receptors 
measured with 123I-R91150 SPECT.  
4. The influence of a single dose of morphine on canine cerebral 5-HT2A receptors 
The aim of the fourth study was to assess the influence of a single intravenous bolus of 
morphine (0.5 mg/kg) on cerebral 5-HT2A receptor binding in dogs using single SPECT with 
the 5-HT2A radioligand 123I-5I-R91150. The 5-HT2A receptor binding was estimated with  
and without morphine pre-treatment in 8 beagle dogs. A significantly decreased 5-HT2A 
receptor binding was found after morphine in the right (P = 0.012) and left (P = 0.040) 
frontal cortices. Our findings support the existence of an interaction between morphine and 5-
HT2A receptor binding in the canine frontal cortex. In the absence of pain and mood 
disorders, morphine decreased the 5-HT2A receptor availability. Whether this is caused by 
decreased receptor density due to direct internalization or the result of indirect actions, such 
as increased endogenous serotonin release, remains to be elucidated. 
5. The influence of prolonged morphine administration on canine cerebral 5-HT2A 
receptors 
The fifth study examined the effect of prolonged opioid treatment on cerebral 5-HT2A 
receptors. Cerebral 5-HT2A receptor availability was estimated in 7 beagle dogs pre and post 
10-day morphine treatment (20 mg twice daily oral sustained release morphine) with 123I-R-




0.05) lowered 5-HT2A receptor binding in the right and left frontal cortex, the right and left 
temporal cortex, the right and left parietal cortex, and the subcortical region. Prolonged 
exposure to morphine decreased the 5-HT2A receptor availability in a large part of the canine 
cortex. This finding gives further evidence for the existence of an interaction between the 
opioid and 5-HT2A receptor system and encourages further research on the possible 
beneficial effects of opioids in the treatment of mood disorders. 
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Het bepalen van regionale hersendoorbloeding is een maat voor hersenactiviteit en kan dus 
gebruikt worden om te achterhalen hoe bepaalde geneesmiddelen werken door te kijken naar 
het regionale doorbloedingspatroon dat een bepaald geneesmiddel creëert. Het biedt 
daarenboven eveneens de mogelijkheid om verschillende geneesmiddelen met elkaar te 
vergelijken door het vergelijken van de geproduceerde doorbloedingspatronen. Dit is in het 
geval van pijnstillers (analgetica) bijzonder interessant. Om de regionale hersendoorbloeding 
bij honden te evalueren hebben voorgaande studies gebruik gemaakt van functionele 
beeldvorming (SPECT) met behulp van de radioactieve tracer 99mTC-ECD. In de humane 
geneeskunde wordt naast 99mTC-ECD, het andere radioligand 99mTc-HMPAO ook frequent 
aangewend voor het bepalen van de regionale hersendoorbloeding en werden deze twee 
radioliganden reeds vaak met elkaar vergeleken. Bij de hond werd dit tot hiertoe nog niet 
gedaan en daarom was de eerste doelstelling van deze doctoraatsthesis het vergelijken van 
99mTC-ECD en 99mTc-HMPAO voor de evaluatie van regionale hersendoorbloeding bij de 
hond. 
1. Vergelijking van de regionale hersendoorbloeding met 99mTC-ECD en 99mTc-
HMPAO bij de hond 
De doelstelling van de eerste studie was onderzoeken of de regionale distributieverschillen 
tussen de twee radioliganden die gezien worden bij de mens, ook bij de hond voorkwamen. 
Acht beagles werden tweemaal onderzocht d.m.v. SPECT, eerst met 99mTc-ECD, gevolgd 
door 99mTc-HMPAO. Er werden verschillen vastgesteld tussen beide radioliganden in de 
subcorticale regio (P = 0.001, ECD > HMPAO) en in mindere mate in het cerebellum (P = 
0.03, ECD < HMPAO). Deze studie toont aan dat beide radioliganden gebruikt kunnen 
worden voor de bepaling van regionale hersendoorbloeding. Het is echter aangewezen om 
een keuze te maken tussen beide radioliganden gezien de regionale verschillen en een 




De volle mu opiaat receptor agonist morfine is een voorbeeldpijnstiller zowel in de 
humane geneeskunde als de diergeneeskunde. Het wordt frequent aangewend in gevallen van 
acute pijn, zoals bijvoorbeeld in het geval van perioperatieve pijnbestrijding. De tweede 
doelstelling van deze doctoraatsthesis was daarom het onderzoeken van de invloed van 
morfine op de regionale hersendoorbloeding om zo meer inzicht te krijgen in het 
werkingsmechanisme van dit opiaat bij de hond.  
2. De invloed van een éénmalige morfine toediening op de regionale 
hersendoorbloeding bij de hond 
De doelstelling van de tweede studie was het onderzoeken van het effect van een 
éénmalige intraveneuze toediening van morfine (0.5 mg/kg) op de regionale 
hersendoorbloeding. Het onderzoek werd uitgevoerd bij 8 beagles volgens een 
gerandomiseerd cross-over design. Er werden telkens 3 SPECT scans gedaan m.b.v. 99mTc-
ECD: baseline, 30 minuten na morfine en 120 minuten na morfine. Er werd een significante 
stijging van de hersendoorbloeding gevonden in de subcorticale regio en de pariëtale regio en 
een daling in de frontale regio in de scans 30 minuten na morfine vergeleken met de baseline 
scans. De subcorticale regio bevat structuren die belangrijk zijn voor pijnmodulatie (o.a. pijn 
inhibitie) en het is daarom niet verrassend dat een pijnstiller in deze regio veranderingen 
veroorzaakt. Dit verschil in doorbloeding was echter niet terug te vinden in de scans 120 
minuten na morfine wat mogelijks zou kunnen wijzen op een tijdsafhankelijk effect van 
morfine. Dit eventuele tijdsafhankelijk effect zou een interessante verdere onderzoekspiste 
kunnen zijn voor latere studies. 
3. De invloed van een langdurige toediening van morfine op de regionale 
hersendoorbloeding bij de hond 
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Het doel van de derde studie was het onderzoeken van het mogelijke effect van een 10-
daagse morfine toediening (20 mg/kg BID orale vertraagde vrijstelling morfine) op de 
regionale hersendoorbloeding. Deze cross-over studie werd uitgevoerd bij 8 beagles op een 
gerandomiseerde wijze. Er werden telkens 2 SPECT scans uitgevoerd m.b.v. 99mTc-HMPAO: 
baseline en na 10 dagen morfine. Op de laatste dag van de morfinebehandeling werden 
eveneens plasmaconcentraties van morfine bepaald om na te gaan of de gebruikte morfine 
dosering voldoende was. De vergelijking van de hersendoorbloeding met en zonder 10 dagen 
morfine toonde geen significante verschillen aan. De plasmaconcentraties van morfine waren 
vergelijkbaar met deze gevonden in de literatuur en zijn klinisch relevant. 
Het is reeds lang gekend dat er een interactie bestaat tussen het opiaat en het serotonerge 
systeem ter hoogte van het ruggenmerg (descenderende pijninhiberende banen), maar ook ter 
hoogte van de hersenen. Deze zogenaamde supraspinale interactie is niet alleen belangrijk 
voor de analgetische eigenschappen van opiaten, maar kan eveneens een rol spelen 1) in de 
mogelijke antidepressieve werking van opiaten (verhoogde 5-HT vrijstelling in de hersenen is 
een hoofdonderdeel van de behandeling van depressie) en 2) in het ontstaan van 
nevenwerkingen door het chronische gebruik van opiaten (downstream-veranderingen in 
bepaalde neurotransmittersystemen wordt gezien als een belangrijk onderdeel van de 
ontwikkeling van deze nevenwerkingen). In het bijzonder werd gezien dat de 5-HT2A 
receptor een mogelijke rol speelt in alle drie de voorgenoemde onderdelen: analgesie, 
depressie en opiaatnevenwerkingen. Daarom was de doelstelling van het derde onderdeel 
van deze doctoraatsthesis het onderzoek naar de invloed van morfine op het 5-HT2A 
receptorsysteem in de hersenen van de hond m.b.v. SPECT.  
4. De invloed van een eenmalige toediening van morfine op 5-HT2A receptoren in de 




De doelstelling van de vierde studie was het onderzoeken van de mogelijke veranderingen 
in 5-HT2A receptorbinding door een eenmalige toediening van morfine (0.5 mg/kg 
intraveneus). De 5-HT2A receptorbinding werd gemeten d.m.v. SPECT en het 5-HT2A 
receptorspecifieke radioligand 123I-R-91150. Bij 8 beagles werden telkens 2 SPECT scans 
uitgevoerd: met en zonder morfine. In de linker en rechter frontale cortex werd een 
significante daling van de 5-HT2A receptorbinding gevonden in de scans na morfine (rechts 
P = 0.012, links P = 0.040). Deze bevindingen ondersteunen het bestaan van een opiaat-
serotonine-interactie in afwezigheid van pijn en/of gemoedsproblemen. De exacte aard van 
deze interactie dient verder uitgediept te worden aangezien met deze studie geen onderscheid 
gemaakt kan worden tussen een directe of indirecte interactie tussen morfine en de 5-HT2A 
receptoren. 
5. De invloed van een langdurige toediening van morfine op de 5-HT2A receptoren in 
de hersenen van de hond 
De doelstelling van de vijfde studie was het onderzoek naar het effect van een 10-daagse 
morfine toediening (20 mg/kg BID orale vertraagde vrijstelling morfine) op het 5-HT2A 
receptorsysteem. De 5-HT2A receptorbinding voor en na 10 dagen morfine werd geëvalueerd 
bij 7 beagles d.m.v. SPECT en het 5-HT2A receptorspecifieke radioligand 123I-R-91150. De 
10-daagse morfine toediening verlaagde de 5-HT2A receptorbinding significant (P ≤ 0.05) in 
de linker en rechter frontale, linker en rechter temporale, linker en rechter pariëtale cortex en 
de subcorticale regio. Het 5-HT2A receptorsysteem werd in een groot deel van de hersenen 
beïnvloed door langdurige morfine toediening wat verder bewijs geeft  voor een link tussen 
het opiaat en serotonerge systeem. Dit moedigt verder onderzoek aan naar andere mogelijke 
interacties tussen beide systemen voor een zoektocht enerzijds naar een betere pijnbestrijding 
en anderzijds naar een betere behandeling voor gemoedsstoornissen zoals depressie. 
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08:27 woensdag 23 oktober, de dakmannen zijn eindelijk de stormpan op het dak aan het 
plaatsen. Geen idee wat het eigenlijk is of doet, want we hebben al 2 jaar kunnen overleven 
zonder. Onder het motto “beter laat dan nooit” zal ik dan ook maar eens aan dit laatste deeltje 
beginnen. 
Als je me zou vragen wat ik de afgelopen jaren geleerd heb, denk ik in de eerste plaats aan 
zelfkennis. En aangezien dat het begin van alle wijsheid is, kom ik er toch wel goed vanaf 
achteraf gezien. De meesten onder jullie zullen wel weten dat het niet gemakkelijk was, de 
route naar de wijsheid. Maar voor niets komt de zon op zeker? Dat heb ik zo nooit echt goed 
begrepen, die uitdrukking. Komt de zon niet op kommando op? Of is de zon het enige dat 
juist wel gratis opkomt? Zo zijn er altijd wel twee kanten aan een verhaal denk ik dan.  
Goed, genoeg gefilosofeerd! Want ik zou zo nog uren kunnen doorgaan over de grote 
vragen in het leven die me bezig houden, in tegenstelling tot de futiliteiten van elke dag. 
Laten we aan de slag gaan met het echte werk, het bedanken van de mensen die me de 
afgelopen jaren gesteund hebben op de één of andere manier. 
Klassiek wordt er gestart met de promotoren en laat ik me nu voor een keer aan de regels 
van het spel houden. Ingeborgh, voor jou hoefde dit niet, zei je, maar ik denk dat het toch een 
essentieel deel van het werk uitmaakt. Dus bij deze wil ik je bedanken in eerste instantie voor 
je geduld en omdat je me de kans hebt gegeven om aan dit project mee te mogen werken. Het 
zal me altijd bij blijven hoe Tim (Bossie) me in mijn laatste jaar zei dat Professor Polis eens 
met mij wou praten. Hij voegde er meteen aan toe dat het niets ernstigs was want hij zal ook 
wel aan mijn gezicht gezien hebben dat ik al alles wat ik mogelijks verkeerd gedaan zou 
kunnen hebben aan het overlopen was. The rest, so they say, is history. Ik was meteen 
gefascineerd door al die neuroscience literatuur, wat niet altijd erg productief was, het bos en 




Co-promotor nummer één, Kathelijne. Ook jou wil ik bedanken omdat ik een ritje mee 
mocht rijden op de scinti-trein! Ik hoop dat er nog veel interessante ritten in het verschiet 
liggen, want het is een bodemloos vat van mogelijkheden, die hersenstudies! Ik zal ook altijd 
met plezier terug denken aan de scinti-etentjes, gezelligheid troef!  
Co-promotor nummer twee, Bart. Dat niet altijd alles loopt zoals gehoopt/gedacht, dat is 
ook een belangrijke les in wetenschap. Jammer dat het deel met de muizen niet zo succesvol 
was, maar de samenwerking met jou en Sylvia is altijd vlot gegaan en ik heb veel van jullie 
geleerd.  
Ik wil ook nog Prof. Duchateau en Prof. Croubels bedanken voor hun bijdrage aan onze 
studies. Statistiek blijft echter nog steeds iets mythisch over zich hebben. An Maes, ook jou 
wil ik bedanken voor de vlotte en fijne samenwerking. André en Stijn, dank jullie wel voor 
de tijd die jullie in het nalezen van mijn thesis hebben gestoken en voor de nuttige 
opmerkingen. Prof. Van Ham, u hebt momenteel waarschijnlijk andere dingen aan uw hoofd, 
maar u hebt toch de tijd genomen om hieraan mee te werken, waarvoor dank! 
Het tweede deel van de bedankingen gaat naar de collega’s die al dan niet dicht betrokken 
waren bij de studies. Als er iets is wat ik zal missen, dan zijn jullie het wel. Ik zou me geen 
betere collega’s kunnen inbeelden. Laten we beginnen met de scinti-collega’s. Vaste rots in 
de branding van in het begin: Tim! Volgens mij zou ik nergens geraakt zijn zonder jouw 
hulp. Eerlijk waar! Ik kon altijd rekenen op jouw hulp, praktisch en theoretisch! En ook wel 
esotherisch soms. “Hoe omgaan met dwaze beesten” en de “40-minuten-regel” zouden 
volwaardige opvolgers kunnen worden van de Ceasar-boeken. Veel succes met je nieuwe 
carriere en binnenkort een wandelingetje en/of pizza? Volgende rotsen: Simon en Eva! (ik 
moet nog opletten dat mijn schip hier niet kapseist) Altijd paraat! Geen hond of muis blijft 
ongescand! Met op de achtergrond steeds een fijne streep muziek! (van Israel’s Ukulele tot 
Hespenrol) Simon, tack så mycket! (lang leve google translate) Eva, laat me maar weten als 
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je nog verbouw-info nodig hebt en misschien komen we mekaar eindelijk eens tegen op een 
concertje!  
Nu over van de rotsen en de branding naar de rustige oase: de bureau! Ondertussen is de 
bezetting alweer veranderd, maar altijd even fijne mensen! Ik denk dat iedereen wel weet dat 
we een leutige bureau hebben, ook zonder decibelmeter in de hand. Valentine, de mama 
(letterlijk en figuurlijk) van de bureau. Onze voorliefde voor het uitwisselen van nieuwtjes 
was misschien niet altijd even productief, maar goed, dat maakte het bureauleven wel 
interessanter! Je bent er ook bijna, komt allemaal goed! Steven, uiteraard was jij de fijnste 
bureaucollega, al was het maar wegens jouw onberispelijke smaak voor muziek! Nogmaals 
succes met je examen! An, wat ik van jou geleerd heb, naast het koken van artisjokken, te 
laat komen in de cinema en het verloren lopen tijdens wandelingen, is dat geen enkel idee te 
gek is! Ine, ook altijd paraat voor een babbel en een wandel! Ik herinner me Sali the early 
years nog, met als hoogtepunt de gemolde bench! Ongelooflijk vond ik dat! Of nog, de grote 
sprong! Maar wat een schatje is het! Je hebt me ook altijd hoop gegeven met de 2-jaar-
regel… ik heb daar zo mijn theorie over ontwikkeld ondertussen, maar dat is voor een andere 
keer! We moeten dringend nog eens bijkletsen! Daniela, living the American Dream! Zoals 
beloofd, een boekje opgestuurd! Een aaitje aan al jouw beestjes daar! 
De bloemetjes (aka de mini’s) zijn ook een beetje collega’s eigenlijk en ze verdienen zeker 
hun plaatsje hier! Allemaal even schattig en ieder zijn eigen karakter! Aster aka hystericus, 
Lelie aka baby, Bloesemie aka viesneusmini, Margriet, de liefste van allemaal, Droguée 
Orchidee, Rosiemosie, Iriiiiiis en Violet, Madelief, mogelijks nog hysterischer dan Aster, en 
Narcissi. Ik zal nog vaak aan jullie terug denken! Hopelijk zullen jullie binnenkort allemaal 
nieuwe thuis met een warm mandje vinden!  
Op naar het volgende onderdeel: de vrienden! Eerst de nieuwe lichting. Soms is het 




Nathalie en Mariella, onder de tweede noemer vallen. Onze uitjes zijn altijd een plezier! 
Nathalie, ik wens je nog veel succes met de laatste loodjes! Mariella, heb je de Martini mee? 
Ik hoop voor jou dat je de job van je leven vind, je weet dat ik dit niet zomaar zeg he! ;-) 
Matthias y Cata, voy a probar de decirlo en español! Estoy muy contenta que he conocido a 
vosotros y que, cuando nos vemos, siempre está una fiesta! Oh boy, I really should take some 
lessons again, because this really is too basic! Anyway, I am so happy to have you amongst 
my friends and I really look forward to going to Colombia with you one day! In the mean 
time, I hope we can enjoy many Lucy changs and Oud Kloosters together!  
De gouden oude vrienden, het zijn er niet veel, en dat maakt ze extra waardevol! Karolien, 
dat jij mama word, vind ik toch echt speciaal. We kennen mekaar immers al van in de 
kleuterklas en hebben samen al vele leuke tijden gehad! Ook al zien we mekaar misschien 
niet zo vaak, ik ben blij dat onze vriendschap blijft duren!  
Piraten, ik ben blij dat ik in jullie team zit en ik zie jullie graag! Ik hoop dat we nog lang 
samen zullen roeien op de zee van het leven! Merel, jij zou hier zo goed in zijn, een lyrisch 
dankwoord met een zwierig rijmpje! Succes met “den bouw”! Nieuw huis, misschien toch 
nog een nieuwe muis? Lies, de tweede piraat met uitbreiding van de vloot! Jullie zien er 
geweldig uit met z’n drieën! No-nonsense en gaan! Leslie, laat u gaan vanavond en daarna 
studeren! Hup hup hup! En in februari gaan we er een lap op geven! Annelieke, van dag 1 
van onze studies, nu al 11 jaar geleden – “mag ik hier zitten?” “JAA!!” –  ben je mijn 
allerbeste pal-o-mine! Van de koffie-drink-uitjes in het Middelheim tot de leerrijke vakanties 
in Frankrijk (Obladie oblada!)! Ik ben blij dat je je geluk gevonden hebt in Frankrijk en: A 
très bientôt, petit Elvis!  
Next, the familiy in law! Marga en Adrien, bedankt voor alle hulp de afgelopen jaren! De 
weekends in het stof zullen we niet gauw vergeten, maar dat is al een geluk toch al achter de 
rug! Geniet van jullie reis naar Jamaica! (toch nog steeds een beetje jaloers hoor) En daarna 
Dankwoord 
183 	   	  
uitkijken naar New York! Nicky, de kleine broer (hahaha, sorry ik kon het niet laten)! Veel 
plezier daar in Cuba! Breng wat rum mee en we vieren nog wel eens als jullie terug zijn! 
Et puis, la famille! Et elle est grande notre famille! (je m’excuse déjà d’avance pour les 
fautes d’orthographes. Enfin, j’éspère quand-même qu’il y en aura pas trop). Alors, ou 
commencer? Grand-mère, je commence avec toi, vu que tu es au top de la famille! Ça m’a 
toujours fait plaisir de venir étudier chez toi, les bons petits repas (on mange avec les yeux 
comme tu dis toujours) et les pauzes Roland-Garros (vive Nadal!)! On en a eu des 
discussions, toujours très intéressantes. Bien que je dois avouer que ta confiance en 
l’homeopathie reste difficile à comprendre. Je t’embrasse très fort! 
Alors maintenant, ‘les petits’! Vous n’êtes plus tellement petits que ça et ça me fait encore 
toujours drôle de penser qu’on vieillit tous ensemble. En tout cas je peux dire que je suis 
vraiment fière d’être votre grande sœur et je vous aime tous énormément! Timo, mon petit 
frère, arrète de faire le Goron! En avant, marche! (et coupe tes cheveux! ;-) ) Magali-tje, j’ai 
encore souvent pensé à toi ces derniers temps à propos de ce que tu disais sur ‘se rencontrer 
soi-même’. On s’accroche pour la belle aventure: ‘tu vis ta vie et tu t’en sors’ (comme disait 
Tom Barman). Prochaine fois que Buraka passe: tu viens avec! (“avec est un petit bonhomme 
qui se promène jamais tout seul”, mais je m’en fous :-) ) Nuwan, Nunneke, tu vas finir par 
trouvé le truc génial, nec plus ultra qui tue a mort! Avec ton sense du business! :-) Matteo, 
trois mots pour toi: YES YOU CAN! Et puis enfin, Manon! Aaah! L’enfant terrible! (je 
rigole) C’est bête que tu ne sois pas là aujourd’hui! Tu ne peux pas savoir à quel point je suis 
contente que tu m’as aidé ces derniers mois! Sans toi, je ne sais pas à quoi aurait ressemblé 
mon petit livre… (je n’ose même pas y penser) Merci merci merci!!!  
Comme ça on arrive à la source! Mamy! Je ne sais pas très bien quoi dire à vrai dire… J’ai 
pas envie de tomber dans les clichés à deux balles, tu comprends. Ou peut-être qu’il faut y 




galaxie, dans l’univers! ♫ Maman, c’est toi, la plus belle du monde! ♫ Oh non, c’est 
vraiment over-the-top! Je crois que le plus important c’est: Merci de nous avoir fait! Tout les 
six! Et, tu ne t’en rends peut-êre pas compte, de nous avoir donner une enfance, pas comme 
les autres, mais meilleure! Na-na-nère!  
Ik zou ook nog graag mijn beestenboel willen includeren in dit dankwoord. Voor 
dierenvrienden is dit de normaalste zaak van de wereld, voor de anderen, pech gehad, ik zie 
mijn beestjes graag! Mr. White en Raspoutine, de twee dekselse rakkers die gevreesd worden 
door menig planché en zetel. White, je bent een droom van een kat en een zalige extra 
verwarming in de koude wintermaanden. Raspoutini, je bent gewoon vervelend. Maar ook zo 
lief, voila, ik heb het toegegeven, nu goed? En dan de jongste, maar ook de grootste: Caillou. 
Hoewel je het na twee jaar nog steeds niet aan kan in bepaalde situaties, kan ik me geen 
betere huisgenoot inbeelden. Altijd dolenthousiast en klaar voor een babbel, de reden om ’s 
morgens toch maar uit bed te kruipen en een excellente voetverwarmer voor bij het tv kijken! 
Tony, je weet wel. (ja maar ’t is waar he!) Hehe, dat zou wel grappig zijn, om zo af te 
sluiten. We hebben de laatste jaren misschien wat veel hooi op onze vorken genomen, maar 
al bij al staat het huis nog recht! Dat is al een begin! We wonen er nog steeds, samen. Dat is 
ook weer een stap verder. We hebben ons gezinnetje en voorlopig ze is goed zoals ze nu is. 
Nu dit hoofdstuk van mijn/ons leven afgesloten is, is het tijd voor een nieuw hoofdstuk! 
Spannender dan het vorige want laten we eerlijk zijn, dat las niet zo vlot en er ontbraken 
nieuwe en onverwachte wendingen in het verhaal. Ik stel voor iets met magie en draken… 
om mee te beginnen he, daarna zien we wel weer verder. Of nee, toch geen boek, want daar 
komt onvermijdelijk een einde aan en dat wil ik niet. Je weet hoe ik word als een boek 
eindigt… Laten we voor de eindeloze Australische soap gaan. Minus de overtollige drama, 
dan blijven er enkel mooie mensen (wij uiteraard!) en stranden over… Ik zie je graag! 
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